Pregnancy Prevention Programmes in Pharmacovigilance

Introduction

Pregnancy Prevention Programmes (PPPs) represent one of the most comprehensive additional risk minimisation measures used within European pharmacovigilance. They are implemented for medicinal products associated with a significant risk of embryo-fetal toxicity or teratogenicity where routine risk minimisation measures alone are insufficient to prevent exposure during pregnancy.

Unlike individual educational interventions, Pregnancy Prevention Programmes combine multiple coordinated activities, including patient counselling, educational materials, Patient Alert Cards, pregnancy testing, contraception requirements, prescribing controls and continuous effectiveness evaluation. Together, these interventions aim to minimise fetal exposure while preserving access to medicines for patients who may derive substantial therapeutic benefit.

Pregnancy Prevention Programmes require close collaboration between patients, prescribers, pharmacists, Marketing Authorisation Holders and regulatory authorities. Their implementation extends throughout the medicinal product lifecycle and remains closely integrated with the Risk Management Plan and the broader pharmacovigilance system.

This article provides a comprehensive overview of the scientific principles, regulatory framework, implementation, governance, effectiveness evaluation and inspection expectations relating to Pregnancy Prevention Programmes within modern pharmacovigilance.

Learning Objectives

After reading this article you should be able to:

• explain the purpose of Pregnancy Prevention Programmes;
• describe the regulatory framework governing PPPs;
• identify medicines that may require a PPP;
• understand the components of a Pregnancy Prevention Programme;
• describe the responsibilities of patients, prescribers and pharmacists;
• explain governance and lifecycle management;
• understand methods for evaluating programme effectiveness;
• prepare for pharmacovigilance inspections involving Pregnancy Prevention Programmes.

History and Evolution of Pregnancy Prevention Programmes

Pregnancy Prevention Programmes evolved from decades of pharmacovigilance experience demonstrating that exposure to certain medicinal products during pregnancy may result in serious embryo-fetal toxicity, congenital malformations, spontaneous abortion or fetal death. Although product information has long communicated these risks, experience showed that routine risk minimisation measures alone were not always sufficient to prevent unintended pregnancy exposure.

Several high-profile safety issues involving teratogenic medicines reinforced the need for more structured approaches to pregnancy risk minimisation. Regulatory authorities recognised that preventing fetal exposure required more than providing information. Effective prevention required coordinated interventions involving prescribers, pharmacists, patients and Marketing Authorisation Holders throughout the treatment lifecycle.

As Risk Management Plans became established within the European pharmacovigilance framework, Pregnancy Prevention Programmes developed into comprehensive additional risk minimisation measures combining education, counselling, pregnancy testing, contraception, controlled prescribing and continuous effectiveness evaluation.

Today, Pregnancy Prevention Programmes represent one of the most comprehensive and closely monitored forms of additional risk minimisation implemented within the European Union.

Regulatory Framework

Pregnancy Prevention Programmes operate within the European legislative and pharmacovigilance framework governing risk management and additional risk minimisation measures.

The principal regulatory foundations include:

• Directive 2001/83/EC, as amended;
• Regulation (EC) No 726/2004, as amended;
• Commission Implementing Regulation (EU) No 520/2012;
• Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems;
• Good Pharmacovigilance Practices (GVP) Module XVI – Risk Minimisation Measures: Selection of Tools and Effectiveness Indicators.

Depending upon the medicinal product, additional conditions of the marketing authorisation or specific regulatory decisions may define detailed Pregnancy Prevention Programme requirements.

Relationship with GVP Module XVI

Pregnancy Prevention Programmes are among the most comprehensive additional risk minimisation measures described within GVP Module XVI.

Module XVI does not prescribe a standard Pregnancy Prevention Programme for all medicinal products. Instead, it establishes principles for selecting additional risk minimisation measures that are scientifically justified, proportionate to the identified safety concern and capable of demonstrating measurable effectiveness.

For medicines associated with significant embryo-fetal risk, Pregnancy Prevention Programmes frequently combine multiple interventions, including:

• educational materials;
• Patient Alert Cards;
• patient counselling;
• prescriber guidance;
• pharmacist guidance;
• pregnancy testing;
• contraception recommendations;
• documentation of programme participation;
• effectiveness evaluation.

The exact design of the programme should reflect the characteristics of the medicinal product and the associated reproductive risks.

Relationship with the Risk Management Plan

Pregnancy Prevention Programmes should be developed as integral components of the Risk Management Plan.

The Risk Management Plan should describe:

• the reproductive safety concern;
• the scientific rationale for the programme;
• programme objectives;
• programme components;
• implementation strategy;
• effectiveness evaluation;
• lifecycle review.

This integration ensures that Pregnancy Prevention Programmes evolve alongside emerging pharmacovigilance knowledge and changes in the benefit-risk profile of the medicinal product.

Why Pregnancy Prevention Programmes Are Needed

Certain medicinal products may cause serious harm to the developing embryo or fetus if exposure occurs during pregnancy.

Depending upon the medicinal product, potential consequences may include:

• major congenital malformations;
• spontaneous abortion;
• fetal death;
• impaired fetal growth;
• developmental abnormalities;
• irreversible organ damage.

Where these risks are significant and preventable, structured Pregnancy Prevention Programmes provide an additional layer of protection beyond routine prescribing information.

The objective is not to eliminate access to beneficial medicines but to minimise fetal exposure while preserving appropriate treatment for patients who may derive substantial therapeutic benefit.

Public Health Objectives

Pregnancy Prevention Programmes support several complementary public health objectives.

These include:

• preventing avoidable fetal exposure;
• improving patient understanding of reproductive risks;
• promoting informed treatment decisions;
• encouraging appropriate contraception where indicated;
• supporting timely pregnancy testing;
• improving communication between patients and healthcare professionals;
• maintaining a favourable benefit-risk balance.

Each programme should define clear objectives that can later be evaluated using objective effectiveness measures.

Scientific Foundation

Pregnancy Prevention Programmes represent structured additional risk minimisation measures developed to reduce fetal exposure to medicinal products associated with significant reproductive risks. By integrating multiple coordinated interventions within the Risk Management Plan, these programmes support informed clinical decision-making, appropriate patient counselling and continuous evaluation while maintaining access to medicines for patients who may benefit from treatment.

Teratogenicity and Embryo-Fetal Risk

Pregnancy Prevention Programmes are founded upon the scientific understanding of reproductive toxicity. Not every medicinal product associated with pregnancy warnings requires a Pregnancy Prevention Programme. Instead, these programmes are reserved for medicines where fetal exposure may result in serious, preventable harm and where additional coordinated risk minimisation measures are expected to reduce that risk.

Understanding the principles of embryo-fetal development and reproductive toxicology helps explain why Pregnancy Prevention Programmes are necessary for certain medicines and why routine product information is insufficient in these circumstances.

Understanding Reproductive Toxicity

Reproductive toxicity describes the adverse effects of medicinal products on reproduction, pregnancy and fetal development.

Potential effects include:

• impaired fertility;
• embryo loss;
• spontaneous abortion;
• congenital malformations;
• fetal growth restriction;
• developmental abnormalities;
• neonatal toxicity.

The nature and severity of these effects depend upon multiple factors including the medicinal product, dose, duration of exposure and timing during pregnancy.

Embryotoxicity, Fetotoxicity and Teratogenicity

Although these terms are often used together, they describe different biological effects.

Embryotoxicity refers to harmful effects occurring during early embryonic development, including embryo loss or failure of normal development.

Fetotoxicity refers to adverse effects occurring after fetal development has progressed, including impaired growth, functional abnormalities or fetal death.

Teratogenicity refers specifically to the ability of a medicinal product to cause structural congenital malformations or permanent developmental abnormalities following exposure during pregnancy.

Understanding these distinctions assists in characterising reproductive risks and selecting appropriate risk minimisation measures.

Critical Periods of Development

The potential consequences of medicinal product exposure vary according to the stage of pregnancy.

During different stages of development, exposure may result in:

• failure of implantation;
• spontaneous abortion;
• structural malformations;
• functional abnormalities;
• impaired neurological development;
• altered fetal growth.

Consequently, the timing of exposure is an important consideration when evaluating reproductive risk and designing Pregnancy Prevention Programmes.

Mechanisms of Drug-Induced Fetal Harm

Medicinal products may interfere with normal fetal development through several biological mechanisms.

Examples include:

• disruption of cell division;
• interference with organ development;
• inhibition of essential metabolic pathways;
• alteration of hormonal signalling;
• impaired placental function;
• direct fetal toxicity.

The mechanism of toxicity influences both the severity of risk and the type of additional risk minimisation measures that may be appropriate.

Sources of Reproductive Safety Evidence

Knowledge regarding reproductive risks develops throughout the medicinal product lifecycle.

Evidence may arise from:

• non-clinical reproductive toxicity studies;
• clinical development programmes;
• pregnancy exposure reports;
• spontaneous adverse reaction reporting;
• pregnancy registries;
• post-authorisation safety studies;
• published scientific literature;
• epidemiological investigations.

As evidence accumulates, organisations may revise reproductive safety information and modify Pregnancy Prevention Programmes accordingly.

Not Every Pregnancy Warning Requires a Pregnancy Prevention Programme

Many medicinal products include warnings regarding use during pregnancy.

However, a Pregnancy Prevention Programme is generally reserved for situations where:

• fetal harm may be severe or irreversible;
• pregnancy exposure is reasonably preventable;
• behavioural interventions are likely to reduce exposure;
• routine prescribing information alone is unlikely to provide sufficient protection.

The decision should therefore reflect both the characteristics of the medicinal product and the anticipated effectiveness of additional risk minimisation measures.

Balancing Maternal Benefit and Fetal Risk

Medicinal products requiring Pregnancy Prevention Programmes often provide substantial therapeutic benefit for serious medical conditions.

Consequently, treatment decisions require careful consideration of:

• maternal disease severity;
• expected therapeutic benefit;
• available alternative treatments;
• potential fetal risks;
• patient preferences;
• opportunities to minimise pregnancy exposure.

The objective of a Pregnancy Prevention Programme is not simply to prevent pregnancy but to enable informed clinical decisions that optimise outcomes for both patients and potential pregnancies.

The Scientific Basis for Pregnancy Prevention Programmes

Pregnancy Prevention Programmes are therefore based upon a combination of:

• reproductive toxicology;
• pharmacovigilance evidence;
• clinical medicine;
• epidemiology;
• behavioural science;
• regulatory science.

This multidisciplinary foundation distinguishes Pregnancy Prevention Programmes from routine prescribing precautions and explains why they represent one of the most comprehensive forms of additional risk minimisation within the European pharmacovigilance system.

Scientific Foundation

Pregnancy Prevention Programmes are implemented for medicinal products associated with significant embryo-fetal risks where additional coordinated interventions are expected to reduce preventable pregnancy exposure. Understanding reproductive toxicology, critical periods of fetal development, mechanisms of fetal harm and the evolving evidence base enables scientifically justified selection and continual refinement of Pregnancy Prevention Programmes within the Risk Management Plan.

Which Medicinal Products Require a Pregnancy Prevention Programme?

Only a small proportion of authorised medicinal products require a formal Pregnancy Prevention Programme. Although many medicines include warnings regarding use during pregnancy, most reproductive risks can be managed through routine risk minimisation measures such as prescribing information, patient counselling and clinical judgement.

A Pregnancy Prevention Programme should be considered only when additional coordinated interventions are necessary to minimise fetal exposure and protect public health.

The decision is based upon the characteristics of the identified reproductive risk, the expected effectiveness of additional risk minimisation measures and the overall benefit-risk balance of the medicinal product.

Regulatory Considerations

Regulatory authorities evaluate several factors when determining whether a Pregnancy Prevention Programme is appropriate.

These include:

• severity of embryo-fetal toxicity;
• strength of available scientific evidence;
• likelihood of pregnancy exposure;
• reversibility of fetal harm;
• effectiveness of routine risk minimisation;
• feasibility of additional interventions;
• anticipated public health benefit.

The objective is to ensure that Pregnancy Prevention Programmes remain proportionate to the identified risk.

Characteristics of Medicines That May Require a Pregnancy Prevention Programme

Medicinal products requiring Pregnancy Prevention Programmes frequently share one or more of the following characteristics:

• established or strongly suspected teratogenicity;
• serious embryo-fetal toxicity;
• irreversible developmental abnormalities;
• high clinical significance of pregnancy exposure;
• predictable opportunities for prevention;
• evidence that additional interventions reduce exposure.

These characteristics distinguish medicines requiring structured Pregnancy Prevention Programmes from those requiring routine pregnancy precautions alone.

Scientific Evidence Supporting a Programme

The decision to introduce a Pregnancy Prevention Programme should be supported by robust scientific evidence.

Evidence may include:

• reproductive toxicity studies;
• clinical development data;
• spontaneous adverse reaction reports;
• pregnancy exposure registries;
• pharmacoepidemiological studies;
• published scientific literature;
• regulatory safety reviews;
• benefit-risk assessments.

The overall body of evidence should demonstrate that additional coordinated measures are justified.

Therapeutic Areas Frequently Associated With Pregnancy Prevention Programmes

Pregnancy Prevention Programmes have commonly been implemented for medicines used in therapeutic areas such as:

• dermatology;
• oncology;
• neurology;
• rheumatology;
• immunology;
• haematology.

The requirement is determined by the reproductive risk of the specific medicinal product rather than by its therapeutic class.

Examples of Medicines Associated With Pregnancy Prevention Programmes

Examples of medicinal products that have been subject to Pregnancy Prevention Programmes in Europe include:

• isotretinoin;
• thalidomide;
• lenalidomide;
• pomalidomide;
• valproate under specific regulatory restrictions.

The design and requirements of each programme differ according to the characteristics of the medicinal product, available scientific evidence and applicable regulatory decisions.

Medicines That Usually Do Not Require a Pregnancy Prevention Programme

Many medicines include warnings advising avoidance during pregnancy but do not require a formal Pregnancy Prevention Programme.

Examples include medicines where:

• reproductive risks are uncertain or limited;
• fetal harm is not severe or irreversible;
• routine counselling is considered sufficient;
• pregnancy exposure is uncommon;
• additional interventions are unlikely to improve patient safety.

In these situations, routine risk minimisation measures generally provide adequate protection.

Balancing Access and Risk Minimisation

Pregnancy Prevention Programmes should not unnecessarily restrict access to effective treatment.

Regulators and Marketing Authorisation Holders should consider:

• disease severity;
• availability of therapeutic alternatives;
• expected treatment benefit;
• potential fetal harm;
• patient preferences;
• practical implementation of the programme.

The objective is to minimise preventable pregnancy exposure while maintaining appropriate access to medicines for patients who require treatment.

Continuous Regulatory Review

The need for a Pregnancy Prevention Programme should be reviewed throughout the medicinal product lifecycle.

Factors that may prompt reassessment include:

• emerging pharmacovigilance data;
• new reproductive toxicity evidence;
• changes in clinical practice;
• effectiveness evaluation findings;
• regulatory recommendations;
• inspection observations.

Programmes should evolve as scientific understanding of reproductive safety continues to develop.

A Risk-Based Regulatory Decision

Pregnancy Prevention Programmes are not determined solely by the presence of pregnancy warnings. They are implemented following a structured assessment demonstrating that additional coordinated interventions are necessary, scientifically justified and capable of reducing preventable fetal exposure.

This risk-based approach ensures that Pregnancy Prevention Programmes remain proportionate while supporting both patient safety and appropriate access to essential medicines.

Scientific Foundation

Pregnancy Prevention Programmes are reserved for medicinal products associated with significant reproductive risks where routine risk minimisation measures are unlikely to provide adequate protection. Decisions to implement a programme should be supported by scientific evidence, integrated within the Risk Management Plan and periodically reassessed throughout the medicinal product lifecycle to ensure that the programme remains appropriate, proportionate and effective.

Core Components of a Pregnancy Prevention Programme

Pregnancy Prevention Programmes are multifaceted risk minimisation systems comprising several coordinated interventions that work together to minimise fetal exposure to medicinal products associated with significant reproductive risks. No single component is sufficient to prevent every unintended pregnancy exposure. Instead, each element addresses a different stage of the patient journey and reinforces the overall objective of preventing avoidable fetal harm.

The exact structure of a Pregnancy Prevention Programme varies according to the characteristics of the medicinal product, the identified reproductive risks and applicable regulatory requirements. However, most programmes contain a common set of core components that operate together throughout the treatment lifecycle.

A Layered Risk Minimisation Strategy

Pregnancy Prevention Programmes apply the principle of multiple layers of protection.

Rather than relying upon one intervention, they combine several complementary measures that collectively reduce the likelihood of pregnancy exposure.

These layers typically include:

• patient selection;
• reproductive risk communication;
• informed clinical decision-making;
• pregnancy testing;
• contraception requirements;
• educational interventions;
• documentation;
• ongoing monitoring;
• effectiveness evaluation.

If one layer fails, the remaining measures continue to provide opportunities to prevent fetal exposure.

Patient Selection

Pregnancy Prevention Programmes begin by identifying patients for whom treatment is appropriate.

Patient selection considers factors such as:

• clinical indication;
• disease severity;
• therapeutic alternatives;
• reproductive potential;
• individual benefit-risk balance;
• ability to comply with programme requirements.

Appropriate patient selection represents the first opportunity to minimise unnecessary fetal exposure.

Risk Communication

Patients should understand the reproductive risks associated with treatment before therapy begins.

Effective communication includes discussion of:

• embryo-fetal risks;
• potential consequences of pregnancy exposure;
• programme requirements;
• contraception recommendations;
• pregnancy testing;
• actions to take if pregnancy is suspected.

Risk communication should support informed decision-making throughout treatment.

Pregnancy Testing

Where required, pregnancy testing provides objective confirmation that treatment is not initiated during pregnancy and may continue to support safe treatment during therapy.

Testing requirements vary according to:

• the medicinal product;
• reproductive risk;
• treatment duration;
• regulatory requirements;
• individual clinical circumstances.

Pregnancy testing should always be interpreted within the broader context of the overall Pregnancy Prevention Programme.

Contraception

Many Pregnancy Prevention Programmes require effective contraception before, during and, where appropriate, after treatment.

Programme requirements commonly specify:

• timing of contraception;
• acceptable contraceptive methods;
• duration following treatment discontinuation;
• counselling requirements;
• management of contraceptive failure.

Contraception requirements should remain evidence-based and proportionate to the reproductive risks associated with the medicinal product.

Educational Measures

Educational interventions reinforce reproductive safety messages for both patients and healthcare professionals.

These may include:

• educational booklets;
• patient guides;
• healthcare professional guides;
• counselling checklists;
• training materials.

Educational measures improve understanding of programme requirements and promote consistent implementation.

Patient Alert Cards

Many Pregnancy Prevention Programmes include Patient Alert Cards.

These provide patients with concise safety information that can be presented during healthcare encounters and reinforce important reproductive risk messages throughout treatment.

Patient Alert Cards complement rather than replace counselling and educational materials.

Responsibilities of Healthcare Professionals

Successful Pregnancy Prevention Programmes depend upon clearly defined professional responsibilities.

Prescribers, pharmacists and other healthcare professionals may be responsible for:

• counselling patients;
• confirming programme eligibility;
• arranging pregnancy testing;
• reviewing contraception;
• issuing educational materials;
• documenting participation;
• reinforcing programme requirements.

Clearly assigned responsibilities promote consistent implementation across healthcare settings.

Patient Responsibilities

Patients also play an essential role in programme success.

Depending upon programme requirements, patients may be expected to:

• understand reproductive risks;
• comply with contraception requirements;
• undergo pregnancy testing;
• report suspected pregnancy promptly;
• attend scheduled follow-up appointments;
• retain programme documentation.

Active patient participation is fundamental to effective pregnancy prevention.

Documentation

Many Pregnancy Prevention Programmes include structured documentation supporting implementation.

Examples include:

• acknowledgement forms;
• counselling records;
• prescribing documentation;
• dispensing documentation;
• pregnancy testing records;
• programme participation records.

Documentation demonstrates implementation while supporting quality management and inspection readiness.

Effectiveness Evaluation

Every Pregnancy Prevention Programme should include predefined methods for evaluating effectiveness.

Evaluation commonly considers:

• implementation;
• patient understanding;
• healthcare professional compliance;
• pregnancy exposure;
• behavioural outcomes;
• clinical outcomes.

Continuous evaluation enables programmes to improve throughout the medicinal product lifecycle.

Governance and Continuous Improvement

Pregnancy Prevention Programmes require ongoing governance to ensure that every component remains scientifically accurate, operationally effective and aligned with current regulatory expectations.

Governance activities include:

• document control;
• change management;
• periodic review;
• effectiveness evaluation;
• CAPA implementation;
• inspection readiness.

Strong governance ensures that all programme components continue to function together as an integrated risk minimisation system.

An Integrated System Rather Than Individual Measures

The effectiveness of a Pregnancy Prevention Programme depends upon the interaction between its individual components rather than the strength of any single intervention.

Patient counselling reinforces educational materials. Pregnancy testing supports prescribing decisions. Contraception reduces the likelihood of fetal exposure. Documentation demonstrates implementation. Effectiveness evaluation identifies opportunities for improvement.

Together, these coordinated activities create a comprehensive system designed to minimise reproductive risks while supporting appropriate access to treatment.

Scientific Foundation

Pregnancy Prevention Programmes are integrated systems comprising multiple complementary risk minimisation measures. Patient selection, counselling, pregnancy testing, contraception, educational interventions, documentation, governance and effectiveness evaluation function collectively to minimise preventable fetal exposure. Their coordinated implementation within the Risk Management Plan provides a structured and evidence-based approach to managing significant reproductive risks throughout the medicinal product lifecycle.

Patient Selection and Identifying Patients of Childbearing Potential

Pregnancy Prevention Programmes apply only to patients for whom pregnancy exposure represents a realistic possibility. Consequently, one of the first responsibilities of the prescribing healthcare professional is to determine whether the programme applies to the individual patient.

This assessment should be performed before treatment begins and should be reviewed whenever changes in the patient's medical, surgical or reproductive status may influence programme requirements.

Accurate identification of patients of childbearing potential ensures that Pregnancy Prevention Programmes remain both effective and proportionate.

What Is Childbearing Potential?

For the purposes of Pregnancy Prevention Programmes, childbearing potential refers to the biological possibility of becoming pregnant.

Assessment should be based upon clinical evaluation rather than assumptions regarding age, relationship status, sexual activity or previous reproductive history.

Healthcare professionals should apply the definitions and criteria specified within the approved product information and programme documentation for the individual medicinal product.

Individual Clinical Assessment

Determining whether a patient has childbearing potential requires individual clinical judgement.

Assessment may include consideration of:

• medical history;
• reproductive history;
• menstrual history where appropriate;
• previous surgical procedures;
• documented menopause;
• underlying medical conditions affecting fertility;
• current reproductive status.

The assessment should be documented according to local clinical practice and programme requirements.

Patients Who May Not Be of Childbearing Potential

Depending upon the approved programme requirements and individual clinical circumstances, Pregnancy Prevention Programme requirements may not apply to patients who have no biological potential to become pregnant.

Examples may include patients with:

• documented bilateral oophorectomy;
• documented hysterectomy;
• confirmed permanent infertility where recognised by programme requirements;
• permanent menopause as defined within the approved programme.

Healthcare professionals should always follow the criteria specified within the approved Pregnancy Prevention Programme for the medicinal product rather than relying upon general assumptions.

Adolescents and Young Adults

Assessment of childbearing potential may require particular care in adolescents and young adults.

Healthcare professionals should consider:

• stage of physical development;
• reproductive maturity;
• applicable clinical guidance;
• legal and ethical requirements;
• appropriate involvement of parents or guardians where required by national legislation.

Counselling should remain respectful, age-appropriate and focused on patient safety.

Patients Receiving Long-Term Therapy

For medicines used over extended periods, childbearing potential should not be regarded as a one-time assessment.

Periodic reassessment may be appropriate because:

• reproductive status may change;
• menopause may occur;
• surgical procedures may alter reproductive potential;
• programme requirements may change following regulatory updates.

Regular review supports continued application of appropriate risk minimisation measures.

Avoiding Assumptions

Experienced healthcare professionals avoid assumptions when determining whether Pregnancy Prevention Programme requirements apply.

Programme decisions should not be based solely upon:

• chronological age;
• marital status;
• sexual orientation;
• current sexual activity;
• previous pregnancies;
• previous infertility assessments.

Instead, decisions should be supported by documented clinical assessment and the approved programme requirements.

Documentation

Assessment of childbearing potential should be documented where required by the Pregnancy Prevention Programme.

Documentation may include:

• date of assessment;
• clinical rationale;
• relevant reproductive history;
• programme eligibility;
• counselling provided;
• planned follow-up.

Appropriate documentation supports continuity of care and demonstrates consistent implementation during pharmacovigilance inspections.

Reassessment Throughout Treatment

Patient eligibility should be reconsidered whenever circumstances change.

Examples include:

• initiation or discontinuation of treatment;
• changes in reproductive status;
• important surgical procedures;
• updated regulatory guidance;
• revisions to the Pregnancy Prevention Programme.

Periodic reassessment helps ensure that programme requirements remain appropriate throughout the treatment lifecycle.

A Clinical Decision Supporting Risk Minimisation

Determining whether a patient has childbearing potential is not an administrative exercise. It is a clinical assessment that determines whether the additional safeguards within the Pregnancy Prevention Programme are required.

Accurate patient selection ensures that programme requirements are applied consistently to patients who may benefit while avoiding unnecessary interventions for those to whom the programme does not apply.

Scientific Foundation

Identification of patients of childbearing potential is a fundamental component of Pregnancy Prevention Programmes. Individual clinical assessment, supported by approved programme criteria and appropriate documentation, ensures that additional risk minimisation measures are applied consistently, proportionately and throughout the treatment lifecycle to minimise preventable fetal exposure.

Pregnancy Testing

Pregnancy testing is a fundamental component of many Pregnancy Prevention Programmes because it provides objective evidence that treatment is not initiated during an established pregnancy and, where required, supports the continued safe use of medicines associated with significant embryo-fetal risk.

Pregnancy testing should not be viewed as an isolated intervention. Instead, it functions alongside patient selection, counselling, contraception, educational materials and ongoing clinical review to reduce the likelihood of fetal exposure throughout treatment.

The exact testing requirements depend upon the medicinal product, approved Pregnancy Prevention Programme and applicable regulatory requirements.

Objectives of Pregnancy Testing

The primary objective of pregnancy testing is to minimise unintended fetal exposure to medicines associated with serious reproductive risks.

Specific objectives include:

• confirming that treatment is not initiated during pregnancy;
• identifying pregnancies as early as possible;
• supporting informed prescribing decisions;
• reinforcing patient counselling;
• providing an opportunity to review programme requirements;
• reducing preventable fetal exposure.

Pregnancy testing therefore represents both a diagnostic activity and an opportunity for ongoing risk communication.

Pregnancy Testing Throughout the Treatment Journey

Depending upon the approved Pregnancy Prevention Programme, pregnancy testing may be performed at several stages of treatment.

These stages may include:

• before treatment initiation;
• during treatment at defined intervals;
• following interruptions in treatment where appropriate;
• after treatment discontinuation where residual reproductive risk remains.

The frequency and timing of testing should always follow the approved product-specific programme and clinical judgement.

Selecting the Appropriate Test

The type of pregnancy test used should be appropriate for the clinical circumstances and the approved programme requirements.

Considerations may include:

• analytical sensitivity;
• timing relative to possible conception;
• reliability of the testing method;
• local clinical practice;
• regulatory recommendations.

Healthcare professionals should ensure that testing methods are suitable for detecting pregnancy within the required clinical timeframe.

Interpreting Pregnancy Test Results

Pregnancy test results should always be interpreted within the wider clinical context.

Interpretation should consider:

• the timing of the test;
• recent menstrual history where relevant;
• possible very early pregnancy;
• medicines that may influence interpretation where applicable;
• symptoms suggestive of pregnancy.

A negative pregnancy test should not be interpreted as eliminating all future risk of pregnancy during treatment.

Understanding the Limitations of Pregnancy Testing

Pregnancy testing reduces risk but cannot eliminate it.

Limitations include:

• testing before detectable human chorionic gonadotropin (hCG) concentrations develop;
• pregnancies occurring after testing;
• testing errors;
• delayed reporting of results;
• failure to repeat testing when required.

For these reasons, pregnancy testing should always be combined with the other components of the Pregnancy Prevention Programme.

Pregnancy Testing and Patient Counselling

Each pregnancy test provides an opportunity to reinforce important reproductive safety messages.

Healthcare professionals should review:

• the purpose of testing;
• ongoing contraception requirements;
• actions to take if pregnancy is suspected;
• the importance of reporting missed menstrual periods where applicable;
• continued compliance with programme requirements.

Repeated counselling improves patient understanding and reinforces risk minimisation throughout treatment.

Documentation of Pregnancy Testing

Where required by the Pregnancy Prevention Programme, pregnancy testing should be documented appropriately.

Documentation may include:

• date of testing;
• type of test performed;
• test result;
• clinical decision following testing;
• counselling provided;
• planned follow-up.

Appropriate documentation supports continuity of care, programme governance and inspection readiness.

Pregnancy Testing Is One Component of the Programme

Pregnancy testing should never be regarded as a substitute for contraception, patient education or clinical judgement.

A negative pregnancy test does not eliminate the possibility of future pregnancy exposure, nor does it replace the need for:

• effective contraception where required;
• patient counselling;
• educational materials;
• regular clinical review;
• ongoing adherence to programme requirements.

Its value lies in supporting the coordinated application of all Pregnancy Prevention Programme components.

Continuous Review of Testing Requirements

Testing requirements may evolve as new scientific evidence emerges.

Marketing Authorisation Holders and regulatory authorities may revise:

• testing schedules;
• recommended testing methods;
• programme documentation;
• implementation procedures;
• effectiveness evaluation strategies.

Healthcare professionals should therefore follow the most current approved Pregnancy Prevention Programme for the specific medicinal product.

Scientific Foundation

Pregnancy testing provides objective confirmation that treatment is not initiated during an established pregnancy and supports the continued implementation of Pregnancy Prevention Programmes throughout therapy. Although pregnancy testing is an essential component of many programmes, it functions most effectively when integrated with patient counselling, contraception, education, clinical judgement and continuous pharmacovigilance oversight to minimise preventable fetal exposure.

Contraception Requirements

Effective contraception is one of the central components of many Pregnancy Prevention Programmes because it reduces the likelihood of fetal exposure to medicinal products associated with significant embryo-fetal risk. Unlike pregnancy testing, which confirms whether pregnancy has already occurred, contraception aims to prevent pregnancy throughout the period during which exposure may result in fetal harm.

Contraception requirements should always follow the approved Pregnancy Prevention Programme for the individual medicinal product. The specific recommendations may differ depending on the mechanism of action of the medicine, the duration of reproductive risk, available scientific evidence and regulatory decisions.

Healthcare professionals should therefore apply product-specific requirements rather than relying upon general principles alone.

Objectives of Contraception Requirements

Within a Pregnancy Prevention Programme, contraception aims to:

• prevent pregnancy before treatment begins;
• minimise the likelihood of pregnancy during treatment;
• protect against residual reproductive risk after treatment where applicable;
• support informed treatment decisions;
• contribute to maintaining a favourable benefit-risk balance.

Contraception therefore represents one component of a coordinated risk minimisation strategy rather than an isolated intervention.

Individualised Contraceptive Planning

Contraception should be discussed on an individual basis.

Healthcare professionals should consider factors including:

• reproductive potential;
• age;
• relevant medical history;
• co-existing medical conditions;
• potential contraindications;
• patient preferences;
• likelihood of adherence;
• approved programme requirements.

Individualised counselling supports both patient autonomy and programme compliance.

Highly Effective Contraception

Many Pregnancy Prevention Programmes specify the use of highly effective contraceptive methods.

The precise definition of acceptable methods should always follow the approved programme for the medicinal product.

Healthcare professionals should avoid applying general assumptions because acceptable contraceptive methods may differ between programmes as new scientific evidence and regulatory recommendations emerge.

Timing of Contraception

Depending upon the approved Pregnancy Prevention Programme, contraception may be required:

• before treatment initiation;
• throughout treatment;
• for a defined period following treatment discontinuation.

The required duration reflects the reproductive characteristics of the medicinal product, including persistence of pharmacological activity and available reproductive safety data.

Patients should receive clear instructions regarding when contraception should begin and when it may be discontinued.

Adherence to Contraception

The effectiveness of a Pregnancy Prevention Programme depends not only upon selecting an appropriate contraceptive method but also upon consistent and correct use.

Healthcare professionals should reinforce:

• the importance of continuous adherence;
• actions to take if contraception is interrupted;
• management of missed doses where relevant;
• the need to report suspected contraceptive failure promptly.

Regular discussion of adherence provides opportunities to identify potential problems before pregnancy occurs.

Contraceptive Failure

Pregnancy Prevention Programmes should include clear guidance regarding suspected or confirmed contraceptive failure.

Patients should understand:

• when to seek medical advice;
• when additional contraceptive measures may be appropriate;
• when pregnancy testing may be required;
• when treatment should be reviewed.

Prompt clinical assessment following contraceptive failure is an important component of preventing fetal exposure.

Pregnancy Planning

Some patients may wish to become pregnant after completing treatment.

Healthcare professionals should provide advice consistent with the approved Pregnancy Prevention Programme regarding:

• discontinuation of treatment;
• required contraception after treatment;
• appropriate timing of pregnancy;
• follow-up assessments where applicable.

Pregnancy planning should be integrated into routine clinical care whenever appropriate.

Counselling About Contraception

Contraception counselling should form part of every consultation involving a Pregnancy Prevention Programme.

Discussion should include:

• reproductive risks associated with the medicinal product;
• approved contraceptive requirements;
• importance of adherence;
• pregnancy testing requirements;
• actions following suspected pregnancy;
• opportunities for patients to ask questions.

Repeated counselling reinforces understanding throughout treatment.

Documentation

Where required by the Pregnancy Prevention Programme, contraception counselling and relevant clinical decisions should be documented.

Documentation may include:

• counselling provided;
• contraceptive method discussed or confirmed;
• patient understanding;
• programme participation;
• follow-up arrangements.

Accurate documentation supports continuity of care, programme governance and pharmacovigilance inspection readiness.

Contraception as Part of an Integrated Programme

Contraception should never be viewed as the sole mechanism for preventing fetal exposure.

Its effectiveness depends upon integration with:

• patient selection;
• pregnancy testing;
• patient counselling;
• educational materials;
• Patient Alert Cards;
• clinical follow-up;
• ongoing pharmacovigilance oversight.

Together, these measures provide multiple complementary safeguards against unintended pregnancy exposure.

Scientific Foundation

Contraception is a key component of many Pregnancy Prevention Programmes because it reduces the likelihood of fetal exposure to medicines associated with significant reproductive risks. Contraceptive requirements should always follow the approved product-specific programme and be implemented alongside pregnancy testing, patient counselling, educational measures and ongoing clinical review to provide coordinated and proportionate risk minimisation throughout the treatment lifecycle.

Patient Counselling

Patient counselling is one of the most important components of a Pregnancy Prevention Programme because it enables patients to understand the reproductive risks associated with treatment and the measures required to minimise fetal exposure. Unlike written educational materials, counselling provides an opportunity for personalised discussion, clarification of misconceptions and shared clinical decision-making.

Counselling should not be regarded as a single event performed before treatment begins. Instead, it should continue throughout therapy and be reinforced whenever programme requirements, treatment plans or reproductive circumstances change.

Effective counselling supports informed decision-making while promoting adherence to the Pregnancy Prevention Programme.

Objectives of Patient Counselling

Patient counselling aims to ensure that patients understand:

• the reproductive risks associated with the medicinal product;
• why a Pregnancy Prevention Programme is required;
• the importance of preventing pregnancy during treatment;
• programme requirements;
• actions required if pregnancy is suspected;
• when to seek medical advice.

Counselling should enable patients to participate actively in protecting their own health and minimising fetal risk.

Shared Decision-Making

Pregnancy Prevention Programmes should support shared decision-making between patients and healthcare professionals.

Discussions should consider:

• the expected benefits of treatment;
• the potential reproductive risks;
• available therapeutic alternatives where appropriate;
• patient preferences;
• individual clinical circumstances.

Shared decision-making promotes informed treatment choices while respecting patient autonomy.

Explaining Reproductive Risks

Healthcare professionals should communicate reproductive risks accurately, consistently and in language appropriate for the individual patient.

Discussion may include:

• the nature of embryo-fetal risk;
• potential consequences of pregnancy exposure;
• uncertainty where evidence is limited;
• factors influencing reproductive risk;
• measures available to minimise exposure.

Risk communication should remain balanced and scientifically accurate while avoiding unnecessary alarm.

Explaining Programme Requirements

Patients should understand each component of the Pregnancy Prevention Programme and why it is necessary.

Topics commonly include:

• pregnancy testing;
• contraception requirements;
• educational materials;
• Patient Alert Cards;
• follow-up appointments;
• documentation requirements;
• reporting suspected pregnancy.

Understanding the rationale behind programme requirements improves long-term adherence.

Confirming Patient Understanding

Counselling should not end when information has been provided.

Healthcare professionals should confirm that patients understand:

• the reproductive risks;
• programme requirements;
• actions required if pregnancy is suspected;
• when to seek medical advice;
• the importance of ongoing adherence.

Open questions and discussion are generally more effective than simply asking whether the patient has understood.

Counselling Throughout Treatment

Patient counselling should continue throughout the treatment lifecycle.

Opportunities for reinforcement include:

• treatment initiation;
• routine follow-up appointments;
• prescription renewals;
• pregnancy testing visits;
• changes to programme requirements;
• updates to safety information.

Repeated counselling reinforces key safety messages and allows emerging concerns to be addressed promptly.

Managing Questions and Misconceptions

Patients may have concerns regarding:

• reproductive risks;
• contraception;
• future pregnancy planning;
• fertility;
• treatment interruption;
• breastfeeding where applicable.

Healthcare professionals should encourage discussion and provide evidence-based information consistent with the approved product information and Pregnancy Prevention Programme.

Addressing misconceptions early helps improve programme adherence and supports informed decision-making.

Documentation of Counselling

Many Pregnancy Prevention Programmes require documentation that counselling has been provided.

Documentation may include:

• date of counselling;
• topics discussed;
• programme requirements reviewed;
• patient questions;
• educational materials issued;
• planned follow-up.

Documentation supports continuity of care and demonstrates programme implementation during audits and pharmacovigilance inspections.

Counselling Is More Than an Administrative Requirement

Experienced healthcare professionals recognise that patient counselling is not simply a regulatory obligation.

It is an opportunity to:

• strengthen therapeutic relationships;
• support informed treatment decisions;
• reinforce safe medicine use;
• identify barriers to adherence;
• reduce preventable pregnancy exposure.

High-quality counselling contributes directly to the overall effectiveness of the Pregnancy Prevention Programme.

A Continuing Clinical Conversation

The most effective Pregnancy Prevention Programmes treat counselling as an ongoing clinical dialogue rather than a single pre-treatment discussion.

As treatment progresses and patient circumstances evolve, counselling should be revisited, updated and reinforced to ensure that patients remain informed, engaged and able to participate actively in minimising reproductive risks throughout the medicinal product lifecycle.

Scientific Foundation

Patient counselling is a cornerstone of Pregnancy Prevention Programmes because it supports informed decision-making, improves understanding of reproductive risks and reinforces adherence to programme requirements. Continuous, patient-centred counselling integrated with pregnancy testing, contraception, educational materials and ongoing clinical review provides a structured approach to reducing preventable fetal exposure while supporting the safe and appropriate use of medicinal products.

Educational Materials Within Pregnancy Prevention Programmes

Educational materials are fundamental components of most Pregnancy Prevention Programmes because they reinforce counselling, promote consistent implementation and communicate essential reproductive safety information throughout treatment. Unlike routine product information, educational materials within a Pregnancy Prevention Programme are specifically designed to support behavioural changes that minimise the likelihood of fetal exposure.

Educational materials should complement, rather than replace, discussions between patients and healthcare professionals. Their purpose is to reinforce key messages, improve understanding of programme requirements and provide a consistent source of approved information throughout the treatment journey.

Objectives of Educational Materials

Educational materials within a Pregnancy Prevention Programme are intended to:

• improve understanding of reproductive risks;
• reinforce counselling provided by healthcare professionals;
• explain programme requirements;
• support informed treatment decisions;
• encourage adherence to contraception requirements where applicable;
• reinforce pregnancy testing schedules;
• explain actions required if pregnancy is suspected.

Every educational resource should support one or more clearly defined risk minimisation objectives.

Different Audiences Require Different Materials

Pregnancy Prevention Programmes frequently include separate educational materials for different audiences.

These may include:

• prescriber guides;
• pharmacist guides;
• patient guides;
• caregiver information where appropriate;
• counselling checklists;
• frequently asked questions;
• visual aids supporting patient discussions.

Each resource should be written for the knowledge, responsibilities and information needs of its intended audience.

Supporting Patient Counselling

Educational materials should reinforce, not replace, clinical counselling.

Healthcare professionals should use educational materials to:

• explain complex reproductive risks;
• illustrate programme requirements;
• reinforce important safety messages;
• answer patient questions;
• provide information for later review.

Providing written information allows patients to revisit important topics after the consultation.

Supporting Healthcare Professionals

Educational materials also promote consistent implementation by healthcare professionals.

Resources may include guidance on:

• programme eligibility;
• patient selection;
• pregnancy testing;
• contraception requirements;
• prescribing conditions;
• dispensing requirements;
• documentation;
• reporting suspected pregnancy exposure.

Standardised educational materials reduce variation in programme implementation across healthcare settings.

Scientific Accuracy and Consistency

Educational materials should remain consistent with:

• the Summary of Product Characteristics;
• the Package Leaflet;
• the Risk Management Plan;
• approved Pregnancy Prevention Programme documentation;
• current regulatory requirements.

Conflicting information may reduce confidence in the programme and contribute to implementation errors.

Readability and Health Literacy

Educational materials should communicate reproductive risks clearly without oversimplifying important scientific information.

Good practice includes:

• plain language;
• logical organisation;
• concise explanations;
• consistent terminology;
• practical recommendations;
• appropriate visual presentation.

Patients should be able to identify the actions expected of them without difficulty.

Maintaining Current Information

Educational materials should be reviewed whenever important changes occur.

Common triggers include:

• updates to reproductive safety information;
• revisions to programme requirements;
• changes to contraception recommendations;
• modifications to pregnancy testing schedules;
• effectiveness evaluation findings;
• regulatory recommendations.

Only current approved educational materials should remain in routine use.

Educational Materials as Part of an Integrated Programme

Educational materials achieve their greatest value when integrated with:

• patient counselling;
• pregnancy testing;
• contraception requirements;
• Patient Alert Cards;
• prescriber responsibilities;
• pharmacist responsibilities;
• effectiveness evaluation.

No single educational resource can prevent pregnancy exposure independently. Instead, educational materials reinforce the coordinated interventions that together comprise the Pregnancy Prevention Programme.

Beyond Information Delivery

Successful educational materials do more than communicate scientific facts.

They support behavioural change by helping patients and healthcare professionals understand:

• why programme requirements exist;
• how reproductive risks can be minimised;
• what actions should be taken throughout treatment;
• when additional medical advice should be sought.

Their contribution should therefore be evaluated as part of the overall effectiveness of the Pregnancy Prevention Programme rather than as isolated educational documents.

Scientific Foundation

Educational materials within Pregnancy Prevention Programmes reinforce counselling, improve understanding of reproductive risks and support consistent implementation of programme requirements. By complementing patient counselling, pregnancy testing, contraception and other additional risk minimisation measures, educational materials contribute to reducing preventable fetal exposure and strengthening the overall effectiveness of the Risk Management Plan.

Patient Alert Cards Within Pregnancy Prevention Programmes

Patient Alert Cards are commonly incorporated into Pregnancy Prevention Programmes because they provide patients with immediate access to essential reproductive safety information throughout treatment. Unlike comprehensive educational materials, Patient Alert Cards communicate a limited number of critical messages that may be required during routine healthcare, emergency medical care or consultations with healthcare professionals unfamiliar with the patient's treatment.

Within a Pregnancy Prevention Programme, the Patient Alert Card reinforces counselling, reminds patients of their responsibilities and supports rapid recognition of programme requirements by healthcare professionals.

The card should always be considered one component of the overall Pregnancy Prevention Programme rather than a substitute for counselling, educational materials or clinical review.

Objectives of the Patient Alert Card

Within a Pregnancy Prevention Programme, the Patient Alert Card aims to:

• remind patients of the reproductive risks associated with treatment;
• reinforce the importance of avoiding pregnancy during treatment;
• encourage patients to inform healthcare professionals that they are receiving the medicine;
• support continuity of care across different healthcare settings;
• provide immediate access to essential safety information;
• reinforce actions required if pregnancy is suspected.

The card should communicate only the information necessary to support immediate clinical decision-making.

Key Information Included on the Card

The content of a Patient Alert Card varies according to the approved Pregnancy Prevention Programme for the medicinal product.

Typical information may include:

• the name of the medicinal product;
• a prominent warning regarding pregnancy exposure;
• the need to avoid pregnancy during treatment;
• instructions to consult a healthcare professional immediately if pregnancy is suspected;
• reminders regarding contraception where applicable;
• reminders to carry the card throughout treatment.

Information should remain concise, scientifically accurate and consistent with approved product information.

Supporting Patient Counselling

The Patient Alert Card reinforces counselling provided during consultations.

Healthcare professionals should explain:

• why the card has been issued;
• what information it contains;
• when it should be presented;
• why it should be carried throughout treatment;
• what actions should be taken if pregnancy is suspected.

Issuing the card without explanation is unlikely to achieve the intended behavioural objectives.

Supporting Continuity of Care

Patients receiving treatment may interact with multiple healthcare professionals during the course of therapy.

These may include:

• specialists;
• general practitioners;
• pharmacists;
• emergency physicians;
• hospital clinicians;
• nurses;
• dentists;
• other healthcare professionals involved in patient care.

The Patient Alert Card helps ensure that important reproductive safety information remains available across these healthcare settings.

Responsibilities of Patients

Patients should understand that the Patient Alert Card forms part of their Pregnancy Prevention Programme.

Patients should be encouraged to:

• carry the card throughout treatment where appropriate;
• present it during healthcare encounters;
• read the information periodically;
• request a replacement if the card is lost or damaged;
• follow the instructions provided if pregnancy is suspected.

Active patient participation supports the effectiveness of the overall programme.

Responsibilities of Healthcare Professionals

Healthcare professionals should recognise the Patient Alert Card as a clinical safety resource rather than simply an informational leaflet.

They should:

• review the card with the patient;
• reinforce the key safety messages;
• confirm continued understanding during follow-up visits;
• replace outdated cards when required;
• ensure that counselling remains consistent with the approved programme.

Regular reinforcement improves long-term adherence to Pregnancy Prevention Programme requirements.

Maintaining Current Information

Patient Alert Cards should be updated whenever important programme changes occur.

Examples include:

• revised reproductive safety information;
• changes to contraception requirements;
• modifications to pregnancy testing schedules;
• updated regulatory recommendations;
• revisions to the Pregnancy Prevention Programme.

Only the current approved version should remain in circulation.

Relationship With Other Programme Components

Within a Pregnancy Prevention Programme, the Patient Alert Card should operate alongside:

• patient counselling;
• educational materials;
• pregnancy testing;
• contraception requirements;
• prescriber responsibilities;
• pharmacist responsibilities;
• effectiveness evaluation.

The card reinforces these activities but cannot replace them.

A Portable Reminder of Reproductive Safety

Unlike educational booklets that are typically reviewed during consultations, Patient Alert Cards accompany patients throughout treatment.

Their value lies in making critical reproductive safety information immediately available whenever treatment decisions are made, ensuring that essential programme messages remain visible throughout the patient's treatment journey.

Scientific Foundation

Patient Alert Cards reinforce Pregnancy Prevention Programmes by providing concise, portable reproductive safety information that supports patient awareness, healthcare professional communication and continuity of care. Integrated with counselling, educational materials, pregnancy testing and contraception requirements, they contribute to reducing preventable fetal exposure while strengthening the overall effectiveness of additional risk minimisation measures.

Prescriber Responsibilities

Prescribers play the central role in implementing Pregnancy Prevention Programmes because they determine whether treatment is appropriate, counsel patients regarding reproductive risks and ensure that programme requirements are followed throughout therapy. Although Pregnancy Prevention Programmes involve multiple stakeholders, prescribers coordinate most clinical activities and remain responsible for integrating programme requirements into routine patient care.

Prescriber responsibilities begin before treatment is initiated and continue throughout the medicinal product lifecycle. Every prescribing decision should balance the expected therapeutic benefits against the potential reproductive risks while ensuring that additional risk minimisation measures are implemented consistently.

Confirming That Treatment Is Appropriate

Before prescribing a medicine subject to a Pregnancy Prevention Programme, healthcare professionals should determine that treatment is clinically appropriate.

This assessment should include consideration of:

• the approved indication;
• disease severity;
• expected therapeutic benefit;
• available treatment alternatives;
• the patient's reproductive potential;
• the individual benefit-risk balance.

Treatment should only proceed when the anticipated clinical benefits outweigh the potential reproductive risks and all programme requirements can reasonably be implemented.

Determining Programme Eligibility

Prescribers should determine whether the Pregnancy Prevention Programme applies to the individual patient.

This includes assessment of:

• childbearing potential;
• relevant medical and reproductive history;
• programme inclusion criteria;
• factors that may influence compliance with programme requirements.

Eligibility should be reassessed whenever clinically relevant circumstances change.

Explaining Reproductive Risks

Prescribers should ensure that patients understand the reproductive risks associated with treatment.

Discussions should include:

• the nature of embryo-fetal risk;
• potential consequences of pregnancy exposure;
• uncertainty where evidence is incomplete;
• the importance of preventing pregnancy during treatment;
• circumstances requiring urgent medical advice.

Risk communication should remain scientifically accurate, balanced and appropriate for the individual patient.

Implementing Programme Requirements

Prescribers are responsible for ensuring that programme requirements are incorporated into routine clinical care.

Depending upon the approved Pregnancy Prevention Programme, this may include:

• confirming pregnancy testing requirements;
• discussing contraception requirements;
• reviewing educational materials;
• issuing or reviewing Patient Alert Cards;
• completing required programme documentation;
• arranging appropriate follow-up.

Each requirement should be implemented according to the approved programme for the medicinal product.

Supporting Shared Decision-Making

Pregnancy Prevention Programmes should support informed treatment decisions rather than replace clinical judgement.

Prescribers should encourage patients to discuss:

• treatment goals;
• reproductive plans;
• concerns regarding programme requirements;
• potential barriers to adherence;
• questions about reproductive safety.

Shared decision-making strengthens therapeutic relationships and promotes informed participation throughout treatment.

Monitoring Throughout Treatment

Responsibilities continue after treatment has begun.

Prescribers should periodically review:

• continued treatment appropriateness;
• adherence to programme requirements;
• changes in reproductive status;
• new safety information;
• patient understanding;
• the need for ongoing counselling.

Regular review enables programme requirements to remain aligned with changing clinical circumstances.

Managing Suspected Pregnancy

If pregnancy is suspected or confirmed during treatment, prescribers should act promptly in accordance with the approved Pregnancy Prevention Programme.

Management may include:

• confirming the pregnancy;
• reviewing treatment urgently;
• discussing potential fetal risks;
• arranging appropriate specialist referral where indicated;
• documenting the event;
• initiating pharmacovigilance reporting where required.

The precise clinical response should follow the approved product information and applicable national guidance.

Documentation Responsibilities

Prescribers should maintain accurate documentation demonstrating implementation of the Pregnancy Prevention Programme.

Documentation may include:

• eligibility assessment;
• counselling provided;
• pregnancy testing where applicable;
• educational materials issued;
• Patient Alert Card issuance;
• programme acknowledgement where required;
• follow-up reviews;
• significant clinical decisions.

Complete documentation supports continuity of care, quality management and inspection readiness.

Working With Other Healthcare Professionals

Successful Pregnancy Prevention Programmes require collaboration across the healthcare system.

Prescribers should communicate effectively with:

• pharmacists;
• specialist nurses;
• primary care physicians;
• hospital clinicians;
• other healthcare professionals involved in patient care.

Consistent communication promotes coordinated implementation of programme requirements.

A Continuous Clinical Responsibility

Prescriber responsibilities do not end once treatment has been initiated. They continue throughout therapy, adapting to changes in the patient's clinical condition, reproductive circumstances and emerging pharmacovigilance knowledge.

By combining sound clinical judgement with consistent implementation of Pregnancy Prevention Programme requirements, prescribers play a central role in reducing preventable fetal exposure while ensuring that patients continue to receive appropriate therapeutic benefit.

Professional Insight

Experienced prescribers recognise that Pregnancy Prevention Programmes are not administrative checklists but structured clinical risk management systems. Their role extends beyond prescribing to encompass patient selection, counselling, ongoing monitoring, multidisciplinary communication and continual reassessment of the benefit-risk balance. Effective implementation of these responsibilities is fundamental to protecting patients and minimising preventable fetal exposure throughout the medicinal product lifecycle.

Pharmacist Responsibilities

Pharmacists are essential participants in Pregnancy Prevention Programmes because they provide an additional opportunity to reinforce reproductive safety messages immediately before medicines are supplied to patients. Although prescribing decisions remain the responsibility of the prescriber, pharmacists contribute significantly to the consistent implementation of programme requirements through patient interaction, counselling and professional communication.

Their responsibilities should always be performed in accordance with the approved Pregnancy Prevention Programme, national legislation and local professional practice standards.

Supporting Safe Supply of Medicines

Before dispensing medicines subject to a Pregnancy Prevention Programme, pharmacists should ensure that dispensing occurs in accordance with the approved programme requirements.

Depending upon the medicinal product and local regulatory requirements, this may include confirming that:

• programme conditions have been met;
• appropriate documentation accompanies the prescription where required;
• dispensing restrictions have been satisfied;
• the medicine is supplied within any approved dispensing timeframe.

Pharmacists should follow the product-specific programme requirements applicable within their jurisdiction.

Reinforcing Patient Counselling

Dispensing provides an important opportunity to reinforce information previously discussed by the prescriber.

Pharmacists may remind patients about:

• the importance of preventing pregnancy during treatment;
• adherence to programme requirements;
• pregnancy testing where applicable;
• contraception requirements;
• actions to take if pregnancy is suspected;
• the need to contact their healthcare professional if concerns arise.

These discussions should reinforce, rather than replace, comprehensive clinical counselling.

Reviewing Educational Materials

Where educational materials form part of the Pregnancy Prevention Programme, pharmacists should help ensure that patients receive and understand the approved resources.

Responsibilities may include:

• confirming that educational materials have been provided;
• encouraging patients to read the materials;
• answering questions within their professional competence;
• directing patients to the prescriber when further clinical advice is required.

Consistent use of approved educational materials supports standardised implementation of the programme.

Reinforcing the Use of Patient Alert Cards

Where Patient Alert Cards are included within the Pregnancy Prevention Programme, pharmacists should encourage patients to use them appropriately.

This may include reminding patients to:

• carry the card throughout treatment where appropriate;
• present it during healthcare encounters;
• replace lost or damaged cards;
• review the information periodically.

Patient Alert Cards reinforce reproductive safety messages between clinical consultations.

Identifying Potential Concerns

Pharmacists may identify situations requiring further discussion with the prescriber.

Examples include:

• uncertainty regarding programme requirements;
• patient questions suggesting misunderstanding;
• concerns regarding adherence;
• disclosure of a suspected pregnancy;
• inconsistent documentation where relevant;
• requests for advice outside the pharmacist's scope of practice.

Timely communication promotes coordinated implementation of the Pregnancy Prevention Programme.

Communication With Prescribers

Effective Pregnancy Prevention Programmes depend upon collaboration between pharmacists and prescribers.

Where appropriate, pharmacists should communicate concerns relating to:

• programme implementation;
• patient understanding;
• dispensing issues;
• suspected pregnancy exposure;
• clarification of prescriptions;
• availability of educational materials.

Clear communication supports continuity of care and helps reduce implementation errors.

Documentation

Where required by local procedures or the approved Pregnancy Prevention Programme, pharmacists should maintain appropriate records relating to programme implementation.

Documentation may include:

• dispensing records;
• educational materials supplied;
• Patient Alert Card provision where applicable;
• counselling provided where documented locally;
• communications with prescribers;
• relevant interventions.

Appropriate documentation supports quality assurance and inspection readiness.

Professional Responsibilities

Pharmacists should remain familiar with:

• the approved Pregnancy Prevention Programme;
• current product information;
• relevant educational materials;
• updates to programme requirements;
• applicable professional guidance.

Ongoing professional education helps ensure that reproductive safety information remains current and consistent.

Supporting the Patient Throughout Treatment

Many patients obtain repeat prescriptions from the same pharmacy over extended periods.

These encounters provide valuable opportunities to:

• reinforce key safety messages;
• encourage adherence to programme requirements;
• answer routine questions;
• identify changes that may require referral to the prescriber;
• support continuity of care.

Regular interaction allows pharmacists to contribute meaningfully to the long-term effectiveness of the Pregnancy Prevention Programme.

A Collaborative Role in Risk Minimisation

Pharmacists contribute to Pregnancy Prevention Programmes by reinforcing approved safety information, supporting patient understanding and collaborating closely with prescribers and other healthcare professionals.

Although individual responsibilities vary according to national practice and product-specific programme requirements, pharmacists provide an important additional safeguard against preventable fetal exposure by promoting consistent implementation of reproductive risk minimisation measures throughout the patient's treatment journey.

Professional Insight

Experienced pharmacists recognise that Pregnancy Prevention Programmes extend beyond the safe supply of medicines. Through patient education, reinforcement of counselling, identification of potential implementation issues and effective communication with prescribers, pharmacists strengthen the coordinated system of additional risk minimisation measures designed to minimise preventable fetal exposure while supporting the appropriate use of medicinal products.

Patient Responsibilities

Pregnancy Prevention Programmes are designed to support patients in making informed treatment decisions while minimising the risk of fetal exposure to medicines associated with significant reproductive risks. Although healthcare professionals coordinate many aspects of the programme, its success ultimately depends upon active patient participation throughout treatment.

Patients should understand that Pregnancy Prevention Programmes are intended to protect both their own health and the health of a potential pregnancy. Participation requires ongoing communication with healthcare professionals, adherence to programme requirements and prompt reporting of relevant changes in reproductive circumstances.

Understanding the Purpose of the Programme

Patients should understand why they have been enrolled in a Pregnancy Prevention Programme.

Healthcare professionals should ensure that patients understand:

• the reproductive risks associated with the medicine;
• why additional risk minimisation measures are required;
• the objectives of the programme;
• their own responsibilities throughout treatment;
• the importance of ongoing participation.

Understanding the purpose of the programme encourages informed engagement rather than simple compliance.

Participating in Shared Decision-Making

Patients should actively participate in treatment decisions.

This includes discussing:

• treatment goals;
• expected benefits;
• reproductive plans;
• concerns regarding treatment;
• questions about programme requirements;
• potential barriers to adherence.

Open communication enables healthcare professionals to tailor advice to individual clinical circumstances.

Following Programme Requirements

Patients should follow the requirements of the approved Pregnancy Prevention Programme throughout treatment.

Depending upon the medicinal product, these requirements may include:

• attending scheduled appointments;
• undergoing pregnancy testing where required;
• following contraception requirements;
• reviewing educational materials;
• carrying a Patient Alert Card;
• attending routine follow-up visits.

Participation in these activities strengthens the overall effectiveness of the programme.

Communicating Changes Promptly

Patients should promptly inform their healthcare professional about any changes that may affect the Pregnancy Prevention Programme.

Examples include:

• suspected pregnancy;
• confirmed pregnancy;
• changes in reproductive plans;
• interruption of contraception where applicable;
• difficulty complying with programme requirements;
• adverse effects affecting treatment adherence.

Early communication allows timely clinical assessment and appropriate management.

Reporting Suspected Pregnancy

If pregnancy is suspected during treatment or during any post-treatment period specified within the approved programme, patients should contact their healthcare professional immediately.

Prompt reporting allows:

• confirmation of pregnancy where appropriate;
• urgent review of treatment;
• specialist clinical assessment;
• counselling regarding available options;
• appropriate pharmacovigilance reporting where required.

Patients should never delay seeking medical advice because of uncertainty or concern.

Using Educational Materials

Educational materials should be regarded as practical resources that support safe medicine use throughout treatment.

Patients should be encouraged to:

• read the materials carefully;
• retain them for future reference;
• review them periodically;
• discuss any questions with their healthcare professional.

Educational materials reinforce important information provided during clinical consultations.

Carrying the Patient Alert Card

Where a Patient Alert Card forms part of the Pregnancy Prevention Programme, patients should understand its purpose and use.

Patients should:

• carry the card throughout treatment where appropriate;
• present it during healthcare encounters;
• replace it if it is lost or damaged;
• review the information periodically.

The card supports continuity of care by ensuring that essential reproductive safety information remains readily available.

Attending Follow-Up Appointments

Pregnancy Prevention Programmes require ongoing clinical review.

Patients should attend scheduled appointments to:

• review continued treatment appropriateness;
• discuss reproductive health;
• reinforce programme requirements;
• receive updated counselling;
• review any changes to programme documentation.

Regular follow-up enables programme requirements to remain aligned with changing clinical circumstances.

Asking Questions

Patients should feel comfortable asking questions throughout treatment.

Topics may include:

• reproductive risks;
• pregnancy planning;
• contraception;
• programme requirements;
• treatment alternatives;
• future family planning where appropriate.

Encouraging discussion supports informed decision-making and strengthens the therapeutic relationship.

Patients as Partners in Risk Minimisation

Pregnancy Prevention Programmes are most effective when patients participate actively rather than viewing programme requirements as administrative obligations.

By maintaining open communication with healthcare professionals, attending follow-up appointments, understanding programme requirements and reporting important changes promptly, patients become active partners in protecting both their own health and the health of potential pregnancies.

Patient Perspective

Pregnancy Prevention Programmes rely upon informed and active patient participation. Understanding reproductive risks, maintaining communication with healthcare professionals, following programme requirements and reporting important changes promptly enable patients to play a central role in reducing preventable fetal exposure while receiving appropriate treatment for their underlying medical condition.

Documentation and Acknowledgement Forms

Documentation is an essential component of Pregnancy Prevention Programmes because it provides evidence that programme requirements have been implemented consistently throughout the patient's treatment journey. Appropriate documentation supports continuity of care, facilitates communication between healthcare professionals and demonstrates implementation during audits and pharmacovigilance inspections.

Documentation should reflect the approved Pregnancy Prevention Programme for the individual medicinal product and should be maintained in accordance with applicable regulatory requirements, organisational procedures and local clinical practice.

Objectives of Documentation

Documentation within a Pregnancy Prevention Programme serves several important purposes.

These include:

• recording implementation of programme requirements;
• supporting continuity of patient care;
• facilitating communication between healthcare professionals;
• demonstrating compliance with approved programme requirements;
• supporting pharmacovigilance inspections;
• enabling quality assurance and continuous improvement.

Documentation should accurately reflect clinical activities rather than being completed solely to satisfy administrative requirements.

Types of Documentation

Depending upon the approved programme, documentation may include:

• patient eligibility assessments;
• reproductive risk assessments;
• counselling records;
• pregnancy testing records;
• contraception discussions;
• educational material distribution;
• Patient Alert Card issuance;
• follow-up assessments;
• communications between healthcare professionals;
• programme completion or discontinuation records.

The documentation requirements vary according to the medicinal product and the approved Pregnancy Prevention Programme.

Acknowledgement Forms

Many Pregnancy Prevention Programmes include acknowledgement forms completed by patients and, in some programmes, by healthcare professionals.

These forms typically document that:

• reproductive risks have been discussed;
• programme requirements have been explained;
• educational materials have been provided where required;
• the patient has had an opportunity to ask questions;
• the responsibilities of both the patient and healthcare professionals have been reviewed.

Acknowledgement forms support consistent implementation but should not be interpreted as replacing ongoing clinical communication.

Acknowledgement Is Not the Same as Consent

Acknowledgement forms and informed consent serve different purposes.

Within a Pregnancy Prevention Programme, an acknowledgement form generally documents that important information has been communicated and discussed. It does not replace informed consent where consent is required by clinical practice, research protocols or applicable legislation.

Healthcare professionals should ensure that patients understand programme requirements rather than focusing solely on obtaining signatures.

Maintaining Accurate Records

Documentation should be:

• complete;
• accurate;
• contemporaneous;
• legible;
• readily retrievable;
• consistent with other programme records.

Corrections should follow established documentation practices and preserve the integrity of the clinical record.

Reliable documentation supports both patient care and pharmacovigilance governance.

Supporting Communication Between Healthcare Professionals

Pregnancy Prevention Programmes frequently involve several healthcare professionals.

Documentation supports effective communication by recording:

• programme eligibility;
• counselling provided;
• pregnancy testing status where applicable;
• educational materials supplied;
• follow-up plans;
• clinically significant decisions.

Consistent documentation reduces the risk of misunderstandings when care is shared between different healthcare settings.

Electronic Documentation

Many organisations now manage Pregnancy Prevention Programme records using electronic health records or other validated electronic systems.

Electronic documentation may improve:

• accessibility;
• traceability;
• version control;
• audit trails;
• retrieval during inspections;
• long-term record management.

Electronic systems should comply with applicable regulatory and organisational requirements for data integrity and record retention.

Record Retention

Documentation relating to Pregnancy Prevention Programmes should be retained in accordance with:

• applicable legislation;
• pharmacovigilance requirements;
• organisational record retention policies;
• national healthcare regulations.

Appropriate record retention supports future clinical care, inspections, audits and regulatory enquiries.

Documentation as Evidence of Programme Implementation

Documentation should demonstrate that Pregnancy Prevention Programme requirements have been incorporated into routine clinical practice.

During audits and inspections, documentation may be used to verify:

• consistent implementation;
• patient counselling;
• completion of programme activities;
• communication between healthcare professionals;
• adherence to approved procedures.

Comprehensive documentation strengthens confidence in the effectiveness and governance of the Pregnancy Prevention Programme.

Supporting Continuous Improvement

Documentation also provides valuable information for evaluating and improving Pregnancy Prevention Programmes.

Review of programme records may identify:

• recurring implementation challenges;
• opportunities to improve counselling;
• documentation inconsistencies;
• training needs;
• process improvements;
• areas requiring corrective and preventive action.

Well-maintained documentation therefore contributes not only to regulatory compliance but also to continual improvement in patient safety.

Scientific Foundation

Documentation provides objective evidence that Pregnancy Prevention Programme requirements have been implemented consistently throughout the patient journey. Accurate records, acknowledgement forms, structured communication and appropriate record management support continuity of care, pharmacovigilance governance, inspection readiness and the continual improvement of reproductive risk minimisation activities.

Governance and Lifecycle Management

Pregnancy Prevention Programmes require structured governance throughout the medicinal product lifecycle to ensure that they remain scientifically justified, operationally effective and aligned with current regulatory requirements. Governance extends beyond the development of educational materials or programme documentation and encompasses the systems, processes and oversight necessary to maintain programme quality and effectiveness over time.

Marketing Authorisation Holders should manage Pregnancy Prevention Programmes as controlled pharmacovigilance activities integrated within the wider Risk Management System.

Governance Objectives

The governance framework for a Pregnancy Prevention Programme should ensure that:

• programme requirements remain scientifically justified;
• implementation remains consistent across healthcare settings;
• programme documentation remains current;
• responsibilities are clearly defined;
• effectiveness is evaluated periodically;
• emerging safety information is incorporated promptly;
• opportunities for improvement are identified and implemented.

Strong governance supports both regulatory compliance and the continual protection of patients.

Integration with the Risk Management Plan

Pregnancy Prevention Programmes should be fully integrated within the Risk Management Plan.

The Risk Management Plan should describe:

• the reproductive safety concern;
• the rationale for the programme;
• programme objectives;
• additional risk minimisation measures;
• implementation strategy;
• effectiveness evaluation methods;
• review procedures.

Any significant changes to the Pregnancy Prevention Programme should be reflected within the Risk Management Plan where appropriate.

Roles and Responsibilities

Successful governance depends upon clearly defined organisational responsibilities.

Depending upon the organisation, responsibilities may involve:

• Pharmacovigilance;
• the Qualified Person Responsible for Pharmacovigilance (QPPV);
• Regulatory Affairs;
• Medical Affairs;
• Medical Information;
• Quality Assurance;
• Medical Writing;
• Commercial and Supply functions where appropriate.

Roles should be documented to ensure accountability throughout the programme lifecycle.

Cross-Functional Oversight

Pregnancy Prevention Programmes require collaboration between multiple organisational functions.

Cross-functional oversight helps ensure that:

• educational materials remain aligned with approved product information;
• regulatory commitments are fulfilled;
• programme implementation is coordinated;
• safety information is communicated consistently;
• operational issues are identified promptly.

Regular communication between functional areas promotes efficient programme management.

Change Control

Pregnancy Prevention Programmes should be subject to formal change control.

Changes requiring assessment may include:

• updates to reproductive safety information;
• revised programme requirements;
• modifications to educational materials;
• changes to Patient Alert Cards;
• revised counselling recommendations;
• updated pregnancy testing requirements;
• regulatory requests.

Each change should undergo documented review, approval and implementation before entering routine use.

Version Management

All controlled programme documents should be managed using robust document control procedures.

Version management should include:

• unique document identifiers;
• version numbers;
• approval dates;
• implementation dates;
• scheduled review dates;
• archival of superseded versions.

Only current approved documents should be distributed to healthcare professionals and patients.

Periodic Programme Review

Pregnancy Prevention Programmes should undergo regular review throughout the medicinal product lifecycle.

Review should consider:

• emerging pharmacovigilance data;
• benefit-risk assessments;
• effectiveness evaluation findings;
• pregnancy exposure reports;
• regulatory recommendations;
• inspection observations;
• audit findings;
• changes in clinical practice.

Regular review helps ensure that programme requirements remain proportionate and scientifically justified.

Corrective and Preventive Actions

Programme reviews, audits, inspections and effectiveness evaluations may identify opportunities for improvement.

Corrective and Preventive Actions (CAPAs) may address:

• implementation deficiencies;
• documentation issues;
• educational material revisions;
• healthcare professional training;
• process improvements;
• governance weaknesses.

CAPAs should be tracked to completion and evaluated for effectiveness.

Programme Metrics

Governance should include routine monitoring of programme performance.

Examples of governance metrics include:

• implementation status;
• distribution of educational materials;
• completion of programme reviews;
• document revision timelines;
• training completion;
• effectiveness evaluation milestones;
• CAPA completion;
• inspection observations.

Governance metrics provide early indication of operational issues requiring attention.

Lifecycle Evolution

Pregnancy Prevention Programmes should evolve alongside the medicinal product.

Programme modifications may become necessary following:

• new reproductive safety information;
• changes in the benefit-risk balance;
• updated regulatory guidance;
• improvements in clinical practice;
• effectiveness evaluation findings.

Lifecycle management ensures that the programme remains appropriate throughout the product's marketing authorisation.

Governance Supports Patient Safety

Governance should not be viewed as an administrative activity.

A well-governed Pregnancy Prevention Programme ensures that scientific evidence is translated into consistent clinical practice, regulatory commitments are maintained and opportunities for improvement are identified promptly.

Ultimately, effective governance strengthens the ability of Pregnancy Prevention Programmes to minimise preventable fetal exposure while supporting appropriate access to medicines.

Scientific Foundation

Pregnancy Prevention Programmes require structured governance throughout the medicinal product lifecycle. Integration with the Risk Management Plan, clearly defined organisational responsibilities, robust document control, periodic review, change management and continuous improvement enable Marketing Authorisation Holders to maintain effective additional risk minimisation measures that remain scientifically justified, operationally robust and aligned with evolving pharmacovigilance knowledge.

Evaluating the Effectiveness of Pregnancy Prevention Programmes

The implementation of a Pregnancy Prevention Programme does not, by itself, demonstrate successful risk minimisation. The programme achieves its public health objective only if it reduces preventable pregnancy exposure while allowing appropriate patients to continue receiving beneficial treatment.

For this reason, GVP Module XVI emphasises the importance of evaluating the effectiveness of additional risk minimisation measures using scientifically appropriate methodologies. Pregnancy Prevention Programmes require particularly robust evaluation because they combine multiple coordinated interventions and are intended to prevent serious, potentially irreversible fetal harm.

Effectiveness evaluation should therefore be planned before programme implementation and continue throughout the medicinal product lifecycle.

Objectives of Effectiveness Evaluation

Evaluation should determine whether the Pregnancy Prevention Programme:

• reaches the intended patient population;
• is implemented consistently by healthcare professionals;
• improves understanding of reproductive risks;
• influences patient and healthcare professional behaviour;
• reduces preventable pregnancy exposure;
• continues to provide meaningful public health benefit.

The objective is to understand whether the programme functions as intended under routine clinical practice rather than under ideal conditions.

Planning the Evaluation

Evaluation should be incorporated into programme design from the outset.

Planning should define:

• programme objectives;
• important safety concerns;
• evaluation questions;
• data sources;
• study methodology;
• success criteria;
• review intervals.

Prospective planning ensures that meaningful evidence can be collected throughout the programme lifecycle.

Process Indicators

Process indicators evaluate whether programme activities are being implemented as intended.

Examples include:

• eligible patients enrolled in the programme;
• completion of patient counselling;
• distribution of educational materials;
• provision of Patient Alert Cards;
• pregnancy testing performed where required;
• documentation completed appropriately;
• healthcare professional participation.

These indicators demonstrate implementation but do not necessarily demonstrate reductions in pregnancy exposure.

Outcome Indicators

Outcome indicators evaluate whether the programme achieves its intended clinical and public health objectives.

Examples include:

• patient understanding of programme requirements;
• adherence to contraception requirements where applicable;
• adherence to pregnancy testing schedules;
• healthcare professional knowledge;
• behavioural changes;
• pregnancy exposure during treatment;
• trends in pregnancy-related safety reports.

Outcome indicators provide stronger evidence of programme effectiveness because they assess changes in behaviour and clinical outcomes.

Knowledge and Behaviour Assessments

Many Pregnancy Prevention Programmes include studies assessing knowledge, attitudes and behaviour.

These evaluations may examine whether:

• patients understand reproductive risks;
• healthcare professionals understand programme requirements;
• counselling is effective;
• educational materials improve understanding;
• patients know what to do if pregnancy is suspected;
• programme requirements are followed consistently.

Knowledge alone should not be regarded as evidence of successful risk minimisation unless it results in appropriate behavioural change.

Drug Utilisation Studies

Drug utilisation studies may provide important information regarding programme implementation under routine clinical practice.

Depending upon the study objectives, they may assess:

• prescribing patterns;
• patient populations;
• programme eligibility;
• adherence to prescribing conditions;
• implementation across healthcare settings;
• trends over time.

Drug utilisation studies complement other evaluation methods by describing how medicines are used in real-world clinical practice.

Post-Authorisation Safety Studies

Post-Authorisation Safety Studies (PASS) may be undertaken to evaluate specific aspects of Pregnancy Prevention Programmes.

Examples include studies assessing:

• programme implementation;
• pregnancy exposure;
• reproductive outcomes;
• healthcare professional behaviour;
• patient adherence;
• long-term effectiveness.

PASS may provide valuable evidence supporting continued refinement of programme requirements.

Pregnancy Exposure Monitoring

Pregnancy exposure remains one of the most important outcome measures for Pregnancy Prevention Programmes.

Evaluation may consider:

• reported pregnancies during treatment;
• pregnancy exposure after treatment where relevant;
• timing of exposure;
• programme adherence;
• associated pregnancy outcomes.

Interpretation should recognise that reporting systems may underestimate the true number of pregnancy exposures.

Using Multiple Sources of Evidence

No single evaluation method is sufficient to assess programme effectiveness comprehensively.

Marketing Authorisation Holders should consider combining evidence from:

• process indicators;
• outcome indicators;
• surveys;
• drug utilisation studies;
• PASS;
• pregnancy registries;
• pharmacovigilance data;
• published scientific literature;
• regulatory assessments.

Using complementary evidence strengthens confidence in evaluation findings.

Interpreting Evaluation Findings

Evaluation findings should be interpreted within the broader context of the pharmacovigilance system.

Factors that may influence results include:

• changes in prescribing practice;
• healthcare system differences;
• reporting behaviour;
• evolving scientific knowledge;
• concurrent risk minimisation measures;
• regulatory actions.

Observed changes should therefore be interpreted cautiously using the totality of available evidence.

Continuous Improvement

The purpose of effectiveness evaluation is continual improvement rather than simple regulatory compliance.

Evaluation findings may support decisions to:

• revise educational materials;
• strengthen patient counselling;
• modify programme requirements;
• improve implementation;
• revise effectiveness methodologies;
• introduce additional risk minimisation measures;
• simplify programme components that provide limited value.

Programmes should evolve as new evidence becomes available.

Demonstrating Public Health Benefit

Ultimately, Pregnancy Prevention Programmes should demonstrate that they contribute meaningfully to reducing preventable fetal exposure while supporting appropriate patient access to beneficial treatment.

Effectiveness evaluation provides the evidence needed to determine whether programme objectives continue to be achieved and whether modifications are required to maintain an appropriate balance between patient safety and therapeutic benefit.

Scientific Foundation

Pregnancy Prevention Programmes should undergo continuous effectiveness evaluation using scientifically appropriate methodologies that combine implementation measures, behavioural assessments and clinical outcomes. Integrating process indicators, outcome indicators, drug utilisation studies, PASS, pregnancy exposure monitoring and pharmacovigilance data enables Marketing Authorisation Holders to determine whether programmes continue to reduce preventable fetal exposure and remain appropriate components of the Risk Management Plan throughout the medicinal product lifecycle.

Monitoring, Surveillance and Data Sources

Pregnancy Prevention Programmes should be supported by continuous pharmacovigilance activities that monitor programme implementation, pregnancy exposure and reproductive outcomes throughout the medicinal product lifecycle. Because no single data source provides a complete understanding of programme performance, Marketing Authorisation Holders should integrate evidence from multiple complementary surveillance systems.

The selection of data sources depends upon the objectives of the evaluation, the characteristics of the medicinal product, regulatory commitments and the availability of reliable healthcare data. Combining information from several sources provides a more comprehensive understanding of reproductive safety and the effectiveness of Pregnancy Prevention Programmes.

Objectives of Monitoring

Monitoring activities should aim to:

• detect pregnancy exposures associated with treatment;
• evaluate programme implementation;
• identify emerging reproductive safety concerns;
• assess adherence to programme requirements;
• support benefit-risk assessment;
• provide evidence for continuous programme improvement.

Monitoring should continue throughout the period during which the medicinal product remains subject to a Pregnancy Prevention Programme.

Spontaneous Adverse Event Reports

Spontaneous reporting systems remain an important source of information regarding pregnancy exposure and pregnancy-related adverse outcomes.

Reports may identify:

• exposure during pregnancy;
• medication errors;
• programme implementation failures;
• congenital anomalies;
• spontaneous abortion;
• fetal death;
• neonatal outcomes.

Although spontaneous reporting contributes to signal detection, under-reporting and incomplete clinical information limit its ability to quantify risk or programme effectiveness.

Pregnancy Exposure Reports

Many Marketing Authorisation Holders specifically monitor reports describing exposure during pregnancy.

These reports may provide information regarding:

• timing of exposure;
• duration of treatment;
• adherence to programme requirements;
• pregnancy outcome;
• fetal or neonatal findings;
• contributing clinical factors.

Systematic review of pregnancy exposure reports supports ongoing assessment of programme performance and reproductive safety.

Drug Utilisation Data

Drug utilisation data provide insight into how medicines are prescribed and used in routine clinical practice.

These data may support assessment of:

• prescribing patterns;
• patient populations;
• adherence to programme eligibility criteria;
• implementation across healthcare settings;
• trends over time.

Drug utilisation studies complement clinical safety data by describing real-world medicine use.

Pregnancy Registries

Pregnancy registries provide structured prospective collection of information relating to medicinal product exposure during pregnancy.

Depending upon their design, registries may collect information regarding:

• maternal characteristics;
• timing of exposure;
• pregnancy outcomes;
• fetal development;
• neonatal health;
• longer-term child outcomes.

Registry data may strengthen understanding of reproductive safety where sufficient numbers of exposed pregnancies can be followed.

Post-Authorisation Safety Studies

Post-Authorisation Safety Studies (PASS) may evaluate specific aspects of Pregnancy Prevention Programmes.

PASS may investigate:

• implementation of programme requirements;
• pregnancy exposure;
• healthcare professional behaviour;
• patient adherence;
• programme effectiveness;
• long-term safety outcomes.

These studies frequently provide more detailed evidence than routine pharmacovigilance activities alone.

Literature Monitoring

Published scientific literature contributes important information regarding reproductive safety.

Routine literature surveillance may identify:

• new reproductive toxicity data;
• epidemiological studies;
• pregnancy registry findings;
• case reports;
• systematic reviews;
• meta-analyses;
• evolving clinical recommendations.

Relevant findings should be incorporated into ongoing benefit-risk evaluation and programme review.

Real-World Data Sources

Where available and appropriate, additional sources of real-world evidence may contribute to programme evaluation.

Examples include:

• electronic health records;
• administrative healthcare databases;
• prescription databases;
• insurance claims data;
• congenital anomaly surveillance systems;
• national birth registries.

These sources may provide complementary evidence regarding medicine utilisation and pregnancy outcomes.

Integrating Multiple Data Sources

Each surveillance system has strengths and limitations.

Marketing Authorisation Holders should integrate evidence from multiple sources to develop a comprehensive understanding of:

• programme implementation;
• reproductive safety;
• pregnancy exposure;
• behavioural outcomes;
• emerging safety concerns;
• effectiveness of risk minimisation measures.

Triangulation of evidence provides greater confidence than reliance upon a single data source.

Supporting Continuous Benefit-Risk Evaluation

Information generated through monitoring and surveillance contributes directly to ongoing benefit-risk assessment.

Findings may support:

• revisions to Pregnancy Prevention Programmes;
• updates to educational materials;
• modifications to counselling;
• changes in programme implementation;
• regulatory discussions;
• updates to the Risk Management Plan.

Continuous surveillance therefore strengthens both pharmacovigilance activities and public health protection throughout the medicinal product lifecycle.

Scientific Foundation

Pregnancy Prevention Programmes should be supported by continuous monitoring using multiple complementary pharmacovigilance data sources. Integration of spontaneous reports, pregnancy exposure reports, drug utilisation studies, pregnancy registries, PASS, literature monitoring and real-world healthcare data enables comprehensive evaluation of programme implementation, reproductive safety and the effectiveness of additional risk minimisation measures throughout the medicinal product lifecycle.

Pregnancy Exposure Monitoring

Pregnancy exposure monitoring is a fundamental pharmacovigilance activity supporting Pregnancy Prevention Programmes. Its objective is to identify, document, follow and evaluate pregnancies occurring during treatment with medicinal products associated with significant reproductive risks. Monitoring enables Marketing Authorisation Holders and regulatory authorities to understand whether Pregnancy Prevention Programmes continue to minimise fetal exposure while providing important information regarding reproductive safety throughout the medicinal product lifecycle.

Pregnancy exposure monitoring should be integrated with routine pharmacovigilance activities, signal management and benefit-risk evaluation rather than functioning as an isolated process.

Objectives of Pregnancy Exposure Monitoring

Pregnancy exposure monitoring seeks to:

• identify pregnancies occurring during treatment;
• detect pregnancies occurring during any defined post-treatment risk period;
• characterise exposure circumstances;
• obtain pregnancy outcome information;
• evaluate adherence to Pregnancy Prevention Programme requirements;
• contribute to benefit-risk assessment;
• support continuous improvement of programme implementation.

These objectives extend beyond simple case collection and contribute to the broader understanding of medicine safety in pregnancy.

Sources of Pregnancy Exposure Reports

Pregnancy exposures may be identified from multiple pharmacovigilance sources.

Common sources include:

• spontaneous adverse event reports;
• reports from healthcare professionals;
• direct patient reports;
• medical information enquiries;
• pregnancy registries;
• published scientific literature;
• post-authorisation safety studies;
• regulatory authority communications.

Each report should be evaluated using established pharmacovigilance procedures.

Initial Case Assessment

Every reported pregnancy exposure should undergo an initial assessment to determine the information available and the need for follow-up.

Initial assessment commonly includes:

• patient demographics;
• medicinal product exposure;
• indication for treatment;
• timing of exposure relative to pregnancy;
• estimated gestational age;
• concomitant medicines;
• relevant medical history;
• reporter details.

This information supports appropriate case processing and follow-up planning.

Importance of Follow-Up

Many pregnancy exposure reports are initially incomplete.

Follow-up is frequently required to obtain information regarding:

• duration of exposure;
• pregnancy progression;
• changes in treatment;
• pregnancy outcome;
• fetal development;
• neonatal findings;
• maternal complications.

Structured follow-up improves the scientific value of pregnancy exposure reports and supports more reliable safety assessment.

Pregnancy Outcomes

Whenever possible, pregnancy outcome information should be obtained through appropriate pharmacovigilance follow-up.

Potential outcomes may include:

• live birth;
• spontaneous abortion;
• elective termination;
• stillbirth;
• congenital anomaly;
• neonatal complication;
• outcome unknown.

Outcome information contributes to ongoing evaluation of reproductive safety and the effectiveness of Pregnancy Prevention Programmes.

Evaluating Programme Performance

Pregnancy exposure reports may also provide information regarding implementation of the Pregnancy Prevention Programme.

Case review may identify:

• missed pregnancy testing;
• non-adherence to contraception requirements;
• inadequate counselling;
• delayed recognition of pregnancy;
• medication errors;
• opportunities for programme improvement.

These findings should be considered during periodic programme review.

Integration With Signal Management

Pregnancy exposure monitoring contributes to routine signal management activities.

Accumulating reports may identify:

• unexpected reproductive risks;
• changes in the frequency of pregnancy exposure;
• new congenital abnormalities;
• trends requiring further investigation;
• opportunities for regulatory action.

Potential signals should be evaluated using established pharmacovigilance processes.

Limitations of Pregnancy Exposure Monitoring

Pregnancy exposure monitoring provides valuable pharmacovigilance information but has recognised limitations.

These include:

• under-reporting;
• incomplete follow-up;
• missing outcome information;
• reporting bias;
• delayed reporting;
• limited denominator data;
• inability to establish incidence from spontaneous reports alone.

These limitations should be considered when interpreting monitoring data.

Contribution to Continuous Improvement

Pregnancy exposure monitoring supports continual refinement of Pregnancy Prevention Programmes.

Monitoring findings may prompt:

• revision of educational materials;
• enhanced counselling;
• changes to programme implementation;
• targeted healthcare professional education;
• updates to the Risk Management Plan;
• additional pharmacoepidemiological studies.

Continuous monitoring ensures that Pregnancy Prevention Programmes evolve alongside emerging scientific knowledge and clinical experience.

Monitoring Supports Public Health

Pregnancy exposure monitoring provides essential evidence regarding both reproductive safety and the real-world performance of Pregnancy Prevention Programmes.

When integrated with signal management, benefit-risk evaluation and other pharmacovigilance activities, pregnancy exposure monitoring enables Marketing Authorisation Holders to identify emerging issues, strengthen programme implementation and continue protecting patients and potential pregnancies throughout the medicinal product lifecycle.

Scientific Foundation

Pregnancy exposure monitoring is a core pharmacovigilance activity that supports Pregnancy Prevention Programmes through systematic identification, follow-up and evaluation of pregnancy exposures. Integration with routine case management, signal management, benefit-risk assessment and continuous programme review enables Marketing Authorisation Holders to strengthen reproductive safety surveillance while refining additional risk minimisation measures throughout the product lifecycle.

Pregnancy Registries

Pregnancy registries are structured observational programmes designed to collect information on pregnancies exposed to medicinal products and to evaluate maternal, fetal and neonatal outcomes under routine clinical practice. Within Pregnancy Prevention Programmes, registries provide an important source of prospective real-world evidence that complements spontaneous adverse event reporting, pregnancy exposure monitoring and other pharmacovigilance activities.

Although not every medicinal product subject to a Pregnancy Prevention Programme requires a pregnancy registry, registries may be established where additional long-term information regarding reproductive safety is needed to support benefit-risk evaluation and regulatory decision-making.

Objectives of Pregnancy Registries

Pregnancy registries seek to generate systematic information regarding the effects of medicinal product exposure during pregnancy.

Common objectives include:

• characterising pregnancy outcomes;
• evaluating fetal and neonatal health;
• identifying congenital anomalies;
• assessing maternal outcomes;
• improving understanding of exposure timing;
• supporting benefit-risk evaluation;
• contributing to regulatory decision-making.

Registry objectives should be defined before enrolment begins and should align with the scientific questions that the registry is intended to address.

Prospective Data Collection

Whenever feasible, pregnancy registries are designed to enrol patients before the pregnancy outcome is known.

Prospective enrolment reduces the risk of selective reporting and allows more complete collection of clinical information throughout pregnancy.

Prospective follow-up also enables consistent collection of exposure data, maternal characteristics and pregnancy outcomes using predefined methodologies.

Information Collected

The exact data collected vary according to the registry design and scientific objectives.

Typical information includes:

• maternal demographics;
• medical history;
• indication for treatment;
• medicinal product exposure;
• timing and duration of exposure;
• concomitant medicines;
• pregnancy history;
• pregnancy progression;
• pregnancy outcome;
• neonatal outcomes;
• congenital anomalies where present.

Some registries also include follow-up beyond birth to evaluate longer-term developmental outcomes.

Follow-Up Throughout Pregnancy

Pregnancy registries commonly collect information at several predefined stages.

Follow-up may occur:

• at enrolment;
• during pregnancy;
• at delivery;
• during the neonatal period;
• during infancy where specified by the registry protocol.

Structured follow-up improves data completeness and supports more reliable interpretation of pregnancy outcomes.

Strengths of Pregnancy Registries

Pregnancy registries provide several advantages compared with routine spontaneous reporting.

These include:

• prospective data collection;
• predefined data elements;
• systematic follow-up;
• improved completeness of information;
• more consistent outcome classification;
• reduced recall bias;
• improved understanding of exposure timing.

These characteristics make pregnancy registries valuable sources of pharmacoepidemiological evidence.

Limitations of Pregnancy Registries

Despite their value, pregnancy registries have recognised limitations.

These may include:

• limited enrolment;
• prolonged recruitment periods;
• loss to follow-up;
• incomplete outcome data;
• selection bias;
• absence of appropriate comparison groups;
• limited statistical power for rare outcomes.

Registry findings should therefore be interpreted alongside evidence obtained from other pharmacovigilance activities.

Relationship With Pregnancy Prevention Programmes

Pregnancy registries support Pregnancy Prevention Programmes by providing information regarding pregnancies that occur despite the implementation of additional risk minimisation measures.

Registry findings may help organisations understand:

• patterns of pregnancy exposure;
• adherence to programme requirements;
• reproductive outcomes following exposure;
• opportunities to strengthen programme implementation;
• changes in the benefit-risk balance.

Registry data therefore contribute to the continual refinement of Pregnancy Prevention Programmes.

Contribution to Benefit-Risk Assessment

Information generated through pregnancy registries contributes directly to ongoing benefit-risk evaluation.

Registry findings may support:

• updates to reproductive safety information;
• revisions to educational materials;
• modifications to counselling recommendations;
• changes to Pregnancy Prevention Programme requirements;
• updates to the Risk Management Plan;
• regulatory discussions regarding reproductive safety.

As evidence accumulates, registry findings may improve understanding of both known and emerging reproductive risks.

Integration With Other Evidence Sources

Pregnancy registries should not be interpreted in isolation.

Their findings should be considered together with:

• spontaneous adverse event reports;
• pregnancy exposure monitoring;
• drug utilisation studies;
• Post-Authorisation Safety Studies (PASS);
• published scientific literature;
• epidemiological investigations;
• benefit-risk assessments.

Integration of multiple evidence sources provides a more comprehensive understanding of reproductive safety than any individual study alone.

Pregnancy Registries as Long-Term Pharmacovigilance Tools

Pregnancy registries represent one of the most valuable approaches for generating prospective real-world evidence regarding medicinal product safety during pregnancy.

When carefully designed and integrated with other pharmacovigilance activities, they strengthen scientific understanding of reproductive risks, support continual evaluation of Pregnancy Prevention Programmes and contribute to evidence-based regulatory decision-making throughout the medicinal product lifecycle.

Scientific Foundation

Pregnancy registries provide structured prospective data regarding medicinal product exposure during pregnancy and associated maternal, fetal and neonatal outcomes. By complementing spontaneous reporting, pregnancy exposure monitoring, PASS and other pharmacovigilance activities, pregnancy registries strengthen reproductive safety surveillance, support benefit-risk assessment and contribute to the continual refinement of Pregnancy Prevention Programmes throughout the product lifecycle.

Post-Authorisation Safety Studies (PASS) in Pregnancy Prevention Programmes

Post-Authorisation Safety Studies (PASS) are important pharmacovigilance tools that generate additional information regarding the safety of authorised medicinal products under real-world conditions of use. Within Pregnancy Prevention Programmes, PASS may be designed to evaluate programme implementation, reproductive safety, pregnancy exposure and the effectiveness of additional risk minimisation measures throughout the medicinal product lifecycle.

PASS complement routine pharmacovigilance activities by addressing predefined scientific questions using structured observational or interventional study methodologies. They provide evidence that supports ongoing benefit-risk evaluation, refinement of Pregnancy Prevention Programmes and regulatory decision-making.

Why PASS Are Performed

Marketing Authorisation Holders or regulatory authorities may require PASS when important questions remain regarding the safe use of a medicinal product after marketing authorisation.

Within Pregnancy Prevention Programmes, PASS may be undertaken to:

• evaluate implementation of programme requirements;
• assess adherence to additional risk minimisation measures;
• monitor pregnancy exposure under routine clinical practice;
• evaluate reproductive outcomes;
• investigate emerging safety concerns;
• support ongoing benefit-risk assessment.

Each study should address clearly defined scientific objectives relevant to reproductive safety.

Regulatory Context

PASS may be:

• imposed as a condition of the marketing authorisation;
• requested following regulatory review;
• included within the Risk Management Plan;
• undertaken voluntarily by the Marketing Authorisation Holder to address important safety questions.

Study design, conduct and reporting should comply with applicable European pharmacovigilance legislation and Good Pharmacovigilance Practices.

Study Designs

Several observational study designs may be appropriate depending upon the research question.

Examples include:

• prospective cohort studies;
• retrospective cohort studies;
• case-control studies;
• nested case-control studies;
• registry-based studies;
• database studies;
• cross-sectional surveys where appropriate.

The selected methodology should be scientifically appropriate for the objectives of the Pregnancy Prevention Programme evaluation.

Study Objectives

PASS undertaken within Pregnancy Prevention Programmes may evaluate:

• implementation of programme requirements;
• healthcare professional compliance;
• patient adherence;
• prescribing behaviour;
• pregnancy exposure rates;
• maternal outcomes;
• fetal outcomes;
• neonatal outcomes;
• effectiveness of additional risk minimisation measures.

Clearly defined objectives support meaningful interpretation of study findings.

Data Sources

PASS may utilise one or more complementary data sources.

Examples include:

• electronic health records;
• administrative healthcare databases;
• prescription databases;
• pregnancy registries;
• hospital records;
• primary care databases;
• patient surveys;
• healthcare professional surveys.

Selection of data sources should reflect the scientific objectives and the availability of reliable information.

Study Endpoints

Endpoints should be selected before the study begins and should align with the predefined objectives.

Examples include:

• programme implementation measures;
• completion of pregnancy testing;
• adherence to contraception requirements;
• pregnancy exposure during treatment;
• pregnancy outcomes;
• congenital anomalies;
• healthcare professional knowledge;
• patient understanding of programme requirements.

Endpoints should be clinically meaningful and capable of addressing the study objectives.

Strengths of PASS

PASS provide several advantages when evaluating Pregnancy Prevention Programmes.

These include:

• assessment under routine clinical practice;
• structured study methodology;
• predefined objectives;
• systematic data collection;
• evaluation of implementation;
• support for causal assessment where appropriate;
• contribution to regulatory decision-making.

PASS frequently provide more comprehensive evidence than routine spontaneous reporting alone.

Limitations of PASS

Like all observational studies, PASS have limitations that should be considered when interpreting findings.

Potential limitations include:

• residual confounding;
• incomplete data;
• selection bias;
• loss to follow-up;
• limited statistical power for rare outcomes;
• differences between healthcare systems;
• changing clinical practice over time.

These limitations highlight the importance of interpreting PASS alongside other pharmacovigilance evidence.

Contribution to Pregnancy Prevention Programmes

PASS findings may identify opportunities to improve Pregnancy Prevention Programmes.

Examples include:

• strengthening educational materials;
• improving patient counselling;
• modifying implementation strategies;
• revising programme documentation;
• updating healthcare professional guidance;
• improving effectiveness evaluation methodologies.

Continuous refinement supports more effective reproductive risk minimisation.

Contribution to Regulatory Decision-Making

PASS findings contribute directly to regulatory evaluation throughout the medicinal product lifecycle.

Study results may support:

• updates to the Risk Management Plan;
• revisions to Pregnancy Prevention Programmes;
• amendments to product information;
• changes to additional risk minimisation measures;
• regulatory recommendations;
• reassessment of the benefit-risk balance.

Scientific evidence generated through PASS therefore plays an important role in maintaining public health.

PASS as Part of the Evidence Ecosystem

PASS should not be considered in isolation.

Their findings should be interpreted alongside:

• spontaneous adverse event reports;
• pregnancy exposure monitoring;
• pregnancy registries;
• drug utilisation studies;
• published scientific literature;
• signal evaluations;
• benefit-risk assessments.

Integrating multiple evidence sources provides the most robust assessment of programme effectiveness and reproductive safety.

Scientific Foundation

Post-Authorisation Safety Studies provide structured real-world evidence regarding the implementation and effectiveness of Pregnancy Prevention Programmes. By evaluating programme performance, pregnancy exposure and reproductive outcomes using scientifically appropriate study designs, PASS strengthen benefit-risk assessment, support regulatory decision-making and enable continual refinement of additional risk minimisation measures throughout the medicinal product lifecycle.

Common Challenges in Pregnancy Prevention Programmes

Although Pregnancy Prevention Programmes are among the most comprehensive additional risk minimisation measures used in pharmacovigilance, their implementation is often complex. Success depends upon coordinated participation by patients, prescribers, pharmacists, Marketing Authorisation Holders and regulatory authorities across diverse healthcare systems.

Understanding the practical challenges encountered during implementation enables organisations to strengthen programme design, improve compliance and enhance patient safety throughout the medicinal product lifecycle.

Maintaining Patient Engagement

Pregnancy Prevention Programmes often continue for months or years.

Maintaining patient engagement throughout prolonged treatment may be challenging because:

• programme requirements become routine;
• educational messages lose impact over time;
• treatment goals change;
• patients experience programme fatigue;
• life circumstances evolve.

Regular counselling and reinforcement help sustain understanding and adherence throughout treatment.

Consistent Healthcare Professional Implementation

Programme effectiveness depends upon consistent implementation by healthcare professionals.

Challenges may include:

• differing levels of familiarity with programme requirements;
• staff turnover;
• variable clinical workflows;
• limited consultation time;
• inconsistent documentation practices.

Standardised educational materials and ongoing professional education help reduce variation in implementation.

Communication Across Healthcare Settings

Patients frequently receive care from multiple healthcare providers.

Programme implementation may become more complex when communication is required between:

• hospital specialists;
• primary care physicians;
• pharmacists;
• emergency departments;
• community healthcare providers.

Effective communication supports continuity of care and consistent application of programme requirements.

Balancing Patient Safety and Access to Treatment

Pregnancy Prevention Programmes should minimise preventable fetal exposure without creating unnecessary barriers to treatment.

Healthcare professionals must balance:

• reproductive safety;
• disease severity;
• treatment benefits;
• therapeutic alternatives;
• patient preferences;
• practical implementation.

Maintaining this balance requires careful clinical judgement throughout treatment.

Managing Programme Complexity

Many Pregnancy Prevention Programmes contain multiple interacting components.

These may include:

• counselling;
• pregnancy testing;
• contraception;
• educational materials;
• Patient Alert Cards;
• acknowledgement forms;
• follow-up appointments;
• documentation requirements.

Complex programmes may increase implementation burden for both patients and healthcare professionals, highlighting the importance of clear procedures and practical educational resources.

Keeping Programme Materials Current

Scientific knowledge regarding reproductive safety evolves continuously.

Programme materials may require revision following:

• new safety information;
• regulatory recommendations;
• changes to product information;
• updated contraception guidance;
• effectiveness evaluation findings.

Maintaining alignment across all programme documents requires robust governance and document control.

Measuring Real-World Effectiveness

Demonstrating that a Pregnancy Prevention Programme reduces pregnancy exposure is challenging.

Potential difficulties include:

• incomplete reporting of pregnancy exposure;
• under-reporting within spontaneous reporting systems;
• limited denominator data;
• differences between healthcare systems;
• behavioural factors that are difficult to measure;
• concurrent implementation of multiple risk minimisation measures.

These limitations emphasise the importance of combining multiple complementary evaluation methods.

Adapting to Different Healthcare Systems

Pregnancy Prevention Programmes may be implemented across countries with different:

• healthcare structures;
• prescribing practices;
• dispensing models;
• legal frameworks;
• reimbursement systems;
• professional roles.

While scientific objectives remain consistent, implementation strategies may require adaptation to local healthcare environments.

Supporting Long-Term Governance

Programme effectiveness depends upon sustained organisational commitment.

Marketing Authorisation Holders should maintain:

• cross-functional oversight;
• periodic programme review;
• effectiveness evaluation;
• document control;
• staff training;
• CAPA management;
• inspection readiness.

Strong governance enables organisations to respond promptly to emerging challenges and evolving regulatory expectations.

Learning From Experience

Every Pregnancy Prevention Programme generates valuable experience.

Information obtained through:

• pregnancy exposure monitoring;
• PASS;
• pregnancy registries;
• inspections;
• audits;
• healthcare professional feedback;
• patient feedback;
• regulatory interactions

should be used to improve programme design and implementation.

Continuous learning enables Pregnancy Prevention Programmes to evolve alongside advances in pharmacovigilance science and clinical practice.

Continuous Improvement

Pregnancy Prevention Programmes should not be regarded as static regulatory requirements.

Instead, they should evolve through:

• ongoing scientific evaluation;
• operational experience;
• stakeholder feedback;
• effectiveness studies;
• regulatory review;
• continual quality improvement.

This adaptive approach enables programmes to remain proportionate, practical and effective throughout the medicinal product lifecycle.

Scientific Foundation

Pregnancy Prevention Programmes operate within complex clinical and organisational environments. Addressing challenges relating to patient engagement, healthcare professional implementation, programme governance, effectiveness evaluation and changing scientific knowledge enables Marketing Authorisation Holders to strengthen additional risk minimisation measures while continuing to minimise preventable fetal exposure and protect public health.

Inspection Perspective

Pregnancy Prevention Programmes are among the most closely scrutinised additional risk minimisation measures during pharmacovigilance inspections. Because these programmes are implemented to prevent serious embryo-fetal harm, inspectors expect Marketing Authorisation Holders to demonstrate that every component of the programme is scientifically justified, appropriately governed and effectively implemented throughout the medicinal product lifecycle.

Inspection activities extend beyond reviewing educational materials or programme documentation. Inspectors evaluate whether the Pregnancy Prevention Programme operates as an integrated pharmacovigilance system that continues to reduce preventable pregnancy exposure while supporting the appropriate use of the medicinal product.

Inspection Objectives

During pharmacovigilance inspections, inspectors commonly seek assurance that the Pregnancy Prevention Programme:

• addresses a clearly defined reproductive safety concern;
• is supported by the Risk Management Plan;
• remains scientifically justified;
• has been implemented consistently;
• is supported by appropriate governance;
• undergoes regular effectiveness evaluation;
• is updated when new safety information becomes available.

The emphasis is on demonstrating that the programme functions effectively in routine clinical practice rather than existing solely as documented procedures.

Documentation Commonly Reviewed

Inspectors may request documentation covering the complete lifecycle of the Pregnancy Prevention Programme.

Examples include:

• Risk Management Plans;
• educational materials;
• Patient Alert Cards;
• implementation plans;
• document approval records;
• version histories;
• change control records;
• effectiveness evaluation plans;
• study reports;
• pregnancy exposure monitoring procedures;
• CAPA documentation;
• internal audit reports.

Consistency across these documents provides evidence of robust governance.

Scientific Justification

Inspectors commonly evaluate the scientific rationale supporting the Pregnancy Prevention Programme.

Typical questions include:

• What reproductive risk is the programme intended to address?
• Why are routine risk minimisation measures insufficient?
• Why was a Pregnancy Prevention Programme selected?
• What evidence supports the programme design?
• How are programme components expected to reduce pregnancy exposure?

A clearly documented rationale demonstrates that programme requirements are evidence-based and proportionate.

Programme Implementation

Inspectors evaluate whether programme requirements have been translated into routine practice.

They may review evidence relating to:

• patient selection;
• counselling;
• educational material distribution;
• Patient Alert Card implementation;
• pregnancy testing procedures;
• programme documentation;
• communication with healthcare professionals.

Implementation should be consistent across all regions in which the programme is required, while recognising approved national adaptations where applicable.

Governance and Oversight

Pregnancy Prevention Programmes should operate within an established governance framework.

Inspectors may examine whether organisations have defined:

• programme ownership;
• cross-functional responsibilities;
• document management;
• change control;
• periodic review;
• effectiveness evaluation;
• CAPA management.

Governance should demonstrate continual oversight rather than reactive management.

Effectiveness Evaluation

A central inspection objective is determining whether the Pregnancy Prevention Programme achieves its intended public health objectives.

Inspectors may review evidence relating to:

• implementation metrics;
• process indicators;
• outcome indicators;
• pregnancy exposure monitoring;
• PASS;
• pregnancy registries;
• knowledge and behaviour surveys;
• programme review reports.

Evidence should demonstrate that evaluation findings are used to improve programme performance.

Common Inspection Findings

Inspection observations relating to Pregnancy Prevention Programmes frequently involve:

• inadequate scientific justification;
• inconsistent implementation;
• outdated educational materials;
• weak document control;
• incomplete effectiveness evaluations;
• poor integration with the Risk Management Plan;
• inadequate CAPA management;
• delayed implementation of safety updates.

These findings often indicate weaknesses in pharmacovigilance systems rather than deficiencies in individual programme documents.

Inspection Readiness

Inspection readiness should be maintained continuously throughout the programme lifecycle.

Marketing Authorisation Holders should ensure that:

• programme documentation remains current;
• responsibilities remain clearly assigned;
• educational materials are controlled;
• implementation records are complete;
• effectiveness evaluations are performed as planned;
• governance activities are documented;
• CAPAs are implemented and monitored.

A continuous state of readiness supports both regulatory compliance and organisational learning.

What Inspectors Ultimately Evaluate

Although inspectors review individual programme components, their primary objective is to determine whether the Pregnancy Prevention Programme functions as an effective component of the pharmacovigilance system.

Ultimately, inspectors seek evidence that the programme:

• remains scientifically justified;
• is implemented consistently;
• is governed effectively;
• adapts to emerging safety information;
• demonstrates measurable effectiveness;
• contributes to reducing preventable pregnancy exposure.

The overall focus remains on protecting patients and maintaining a favourable benefit-risk balance throughout the medicinal product lifecycle.

Inspection Insight

During pharmacovigilance inspections, Pregnancy Prevention Programmes are evaluated as integrated, evidence-based risk minimisation systems rather than collections of individual documents. Marketing Authorisation Holders should be prepared to demonstrate the complete lifecycle of the programme—from scientific justification and implementation through governance, effectiveness evaluation and continual improvement—using objective evidence that the programme contributes to reducing preventable fetal exposure while supporting the safe and appropriate use of the medicinal product.

How an Experienced Safety Physician Thinks About Pregnancy Prevention Programmes

Experienced Safety Physicians view Pregnancy Prevention Programmes as clinical risk management systems rather than collections of regulatory requirements. Their objective is not simply to prevent pregnancy exposure but to ensure that patients who require potentially teratogenic medicines receive appropriate treatment while minimising preventable risks to future pregnancies.

Accordingly, Pregnancy Prevention Programmes are approached as structured clinical interventions that combine scientific evidence, patient-centred communication and continuous reassessment throughout treatment.

They Begin With the Clinical Need

Experienced Safety Physicians first consider whether treatment is clinically justified.

Typical questions include:

• What is the severity of the underlying disease?
• What therapeutic benefit is expected?
• Are safer therapeutic alternatives available?
• What are the consequences of delaying or withholding treatment?
• Does the anticipated benefit outweigh the reproductive risk?

Only after establishing that treatment is appropriate do they consider how reproductive risks should be managed.

They Think Beyond Pregnancy

Experienced Safety Physicians recognise that Pregnancy Prevention Programmes are not solely about preventing pregnancy.

They also consider:

• future reproductive plans;
• preservation of long-term health;
• disease control before conception;
• continuity of effective therapy;
• maternal wellbeing;
• potential consequences of treatment interruption.

This broader clinical perspective supports balanced decision-making.

They Individualise Risk Assessment

Experienced Safety Physicians avoid applying Pregnancy Prevention Programmes as rigid protocols.

Instead, they assess each patient's:

• reproductive potential;
• medical history;
• disease characteristics;
• treatment goals;
• capacity to participate in the programme;
• personal preferences.

Individualised assessment enables programme requirements to be implemented proportionately while maintaining patient-centred care.

They Prioritise Communication

Experienced Safety Physicians recognise that successful Pregnancy Prevention Programmes depend upon effective communication rather than documentation alone.

Clinical discussions focus on:

• explaining reproductive risks;
• addressing misconceptions;
• answering patient questions;
• confirming understanding;
• encouraging shared decision-making.

Patients who understand the reasons for programme requirements are more likely to participate actively throughout treatment.

They View Every Consultation as an Opportunity

Programme requirements should not be discussed only when treatment begins.

Experienced Safety Physicians use follow-up appointments to:

• reinforce key safety messages;
• review reproductive plans;
• reassess treatment appropriateness;
• address emerging concerns;
• confirm continued understanding.

Continuous communication strengthens long-term programme effectiveness.

They Expect Human Factors

Experienced Safety Physicians recognise that even well-designed Pregnancy Prevention Programmes cannot eliminate all pregnancy exposures.

Potential contributing factors include:

• misunderstanding;
• communication failures;
• inconsistent implementation;
• changing personal circumstances;
• healthcare system complexity.

Rather than assigning blame, they seek to understand why an exposure occurred and how similar events can be prevented in the future.

They Learn From Every Pregnancy Exposure

Each pregnancy exposure provides an opportunity to improve both clinical practice and pharmacovigilance activities.

Experienced Safety Physicians consider:

• whether programme requirements were followed;
• whether counselling could be improved;
• whether implementation barriers existed;
• whether educational materials remain effective;
• whether additional risk minimisation measures are needed.

Continuous learning strengthens both patient care and future programme design.

They Integrate Pregnancy Prevention Into Overall Patient Care

Pregnancy Prevention Programmes should complement routine clinical practice rather than operate independently.

Experienced Safety Physicians integrate programme activities with:

• disease management;
• benefit-risk assessment;
• patient counselling;
• pharmacovigilance reporting;
• multidisciplinary care;
• long-term treatment planning.

This integrated approach helps ensure that reproductive risk management becomes part of comprehensive patient care.

They Measure Success Through Patient Outcomes

Experienced Safety Physicians do not define success by the number of acknowledgement forms completed or educational materials distributed.

Instead, they evaluate whether Pregnancy Prevention Programmes:

• support informed treatment decisions;
• minimise preventable pregnancy exposure;
• preserve access to appropriate therapy;
• strengthen patient understanding;
• improve long-term clinical outcomes.

Patient protection remains the central objective of every programme.

The Safety Physician Perspective

Ultimately, experienced Safety Physicians ask one fundamental question:

"Have we enabled this patient to receive the right treatment while doing everything reasonably possible to minimise preventable reproductive risk?"

When the answer is yes, the Pregnancy Prevention Programme has fulfilled its purpose as a clinically meaningful risk minimisation intervention rather than simply a regulatory requirement.

Professional Reflection

Experienced Safety Physicians regard Pregnancy Prevention Programmes as patient-centred clinical risk management systems. Through individualised assessment, effective communication, continuous reassessment and integration with routine medical care, they seek to minimise preventable fetal exposure while ensuring that patients continue to receive appropriate and beneficial treatment throughout the medicinal product lifecycle.

How an Experienced QPPV Thinks About Pregnancy Prevention Programmes

An experienced Qualified Person Responsible for Pharmacovigilance (QPPV) views a Pregnancy Prevention Programme as a living pharmacovigilance system that must remain scientifically justified, operationally effective and continuously monitored throughout the medicinal product lifecycle. While healthcare professionals focus on implementing the programme for individual patients, the QPPV focuses on whether the organisation can demonstrate that the programme achieves its intended public health objectives.

For the QPPV, a Pregnancy Prevention Programme is one element of the broader pharmacovigilance system and should be managed with the same level of governance applied to signal management, risk management, post-authorisation safety studies and regulatory compliance.

They Begin With the Risk

Experienced QPPVs begin by understanding the safety concern that justified the Pregnancy Prevention Programme.

They ask:

• What important identified risk is the programme intended to address?
• What scientific evidence supports this risk?
• Why were routine risk minimisation measures considered insufficient?
• Is the programme still justified based on current evidence?
• Does the programme remain proportionate to the identified risk?

Every programme component should be traceable to a clearly documented scientific rationale.

They Think in Systems Rather Than Activities

Experienced QPPVs do not evaluate counselling sessions, educational materials or Patient Alert Cards independently.

Instead, they ask whether the entire system functions effectively.

They consider:

• governance;
• implementation;
• training;
• document control;
• effectiveness evaluation;
• regulatory commitments;
• quality management;
• continuous improvement.

Their focus is on the interaction between these elements rather than on individual documents.

They Expect Objective Evidence

QPPVs understand that regulatory authorities expect evidence rather than assumptions.

Questions commonly include:

• How do we know the programme is being implemented?
• How do we know healthcare professionals understand the requirements?
• How do we know patients understand the risks?
• How do we know pregnancy exposure has been reduced?
• What objective evidence supports these conclusions?

Effective governance depends upon measurable evidence rather than anecdotal experience.

They Integrate Information From Multiple Sources

Experienced QPPVs rarely rely on a single dataset.

Instead, they integrate information from:

• spontaneous adverse event reports;
• pregnancy exposure monitoring;
• pregnancy registries;
• PASS;
• drug utilisation studies;
• literature surveillance;
• audit findings;
• inspection observations;
• regulatory feedback;
• effectiveness studies.

The totality of evidence provides a more reliable assessment than any individual source.

They Challenge Existing Programmes

Experienced QPPVs periodically ask whether the current programme remains appropriate.

Typical questions include:

• Are all programme components still necessary?
• Have new reproductive safety data emerged?
• Can implementation be simplified without reducing patient protection?
• Are healthcare professionals experiencing unnecessary administrative burden?
• Have effectiveness studies identified opportunities for improvement?

They recognise that programmes should evolve as scientific knowledge develops.

They Focus on Governance

Governance is central to the QPPV perspective.

Experienced QPPVs ensure that:

• responsibilities are clearly assigned;
• controlled documents remain current;
• changes undergo formal review;
• effectiveness evaluations are completed;
• CAPAs are implemented;
• regulatory commitments are fulfilled;
• inspection readiness is maintained continuously.

Strong governance ensures that programme quality is sustained over many years.

They Prepare for Regulatory Scrutiny Every Day

Inspection readiness is viewed as a continuous operational state rather than a short-term project.

Experienced QPPVs expect to demonstrate:

• scientific justification;
• programme implementation;
• effectiveness evaluation;
• benefit-risk integration;
• document control;
• organisational oversight;
• continuous improvement.

Evidence should always be available without requiring retrospective reconstruction.

They Learn From Every Observation

Experienced QPPVs regard every pregnancy exposure, audit finding, inspection observation and regulatory recommendation as an opportunity to strengthen the pharmacovigilance system.

Rather than asking:

"Who made the mistake?"

they ask:

• What allowed this to occur?
• Which system controls failed?
• How can recurrence be prevented?
• Should programme requirements be modified?
• Does the Risk Management Plan require updating?

This systems-based approach supports continual improvement.

They Never Consider a Programme Finished

One of the defining characteristics of experienced QPPVs is that they never regard a Pregnancy Prevention Programme as complete.

Instead, they recognise that programmes continually evolve through:

• emerging scientific evidence;
• pharmacovigilance activities;
• effectiveness evaluations;
• regulatory recommendations;
• changing clinical practice;
• organisational learning.

Lifecycle management is therefore regarded as an integral component of pharmacovigilance rather than a separate administrative process.

The QPPV Perspective

Ultimately, experienced QPPVs ask one overarching question:

"Can we demonstrate, using objective scientific evidence, that our Pregnancy Prevention Programme remains justified, effectively implemented, appropriately governed and capable of reducing preventable fetal exposure throughout the product lifecycle?"

When this question can be answered confidently using evidence generated from the pharmacovigilance system, the programme has achieved its purpose as a mature, evidence-based additional risk minimisation measure.

Professional Reflection

Experienced QPPVs view Pregnancy Prevention Programmes as dynamic pharmacovigilance systems rather than static regulatory obligations. Through scientific governance, continuous effectiveness evaluation, multidisciplinary oversight and integration with the Risk Management System, they ensure that programmes continue to protect patients, support regulatory compliance and maintain an appropriate benefit-risk balance throughout the medicinal product lifecycle.

Key Takeaways

• Pregnancy Prevention Programmes (PPPs) are comprehensive additional risk minimisation measures designed to reduce preventable fetal exposure to medicines associated with significant reproductive risks.

• PPPs are implemented when routine risk minimisation measures, such as product information alone, are considered insufficient to adequately protect patients and potential pregnancies.

• The design of every Pregnancy Prevention Programme should be scientifically justified, proportionate to the identified reproductive risk and integrated within the Risk Management Plan.

• Successful Pregnancy Prevention Programmes combine multiple coordinated interventions, including patient selection, counselling, pregnancy testing, contraception requirements, educational materials, Patient Alert Cards, documentation and effectiveness evaluation.

• No single intervention is sufficient to prevent pregnancy exposure. Programme effectiveness depends upon the interaction of all programme components.

• Healthcare professionals should individualise programme implementation according to the approved product-specific requirements, patient characteristics and clinical circumstances.

• Patient counselling is a continuous clinical process that supports informed decision-making and reinforces programme requirements throughout treatment.

• Educational materials and Patient Alert Cards reinforce, but do not replace, discussions between patients and healthcare professionals.

• Documentation provides objective evidence that programme requirements have been implemented consistently and supports continuity of care, governance and inspection readiness.

• Pregnancy exposure monitoring, pregnancy registries, drug utilisation studies and Post-Authorisation Safety Studies provide complementary evidence regarding programme implementation and reproductive safety.

• Effectiveness evaluation should combine implementation measures, behavioural outcomes and clinical outcomes to determine whether the programme continues to achieve its intended public health objectives.

• Pregnancy Prevention Programmes require structured governance, formal change control, document management, periodic review and continuous improvement throughout the medicinal product lifecycle.

• Marketing Authorisation Holders should continually reassess whether programme requirements remain scientifically justified, proportionate and effective as new evidence emerges.

• Pharmacovigilance inspections evaluate Pregnancy Prevention Programmes as integrated risk management systems rather than isolated educational initiatives or documentation exercises.

• The ultimate objective of every Pregnancy Prevention Programme is to minimise preventable fetal exposure while preserving appropriate patient access to medicines that provide meaningful therapeutic benefit.

Continue Reading

Pregnancy Prevention Programmes represent one component of the broader European pharmacovigilance and risk management framework. The following articles provide additional detail on related regulatory concepts, scientific principles and pharmacovigilance activities.

Risk Management

• What Is a Risk Management Plan (RMP)?
• GVP Module V: Risk Management Systems
• Safety Concerns in Risk Management Plans
• Important Identified Risks
• Important Potential Risks
• Missing Information
• Additional Risk Minimisation Measures
• Routine Risk Minimisation Measures

Risk Minimisation

• GVP Module XVI: Risk Minimisation Measures
• Educational Materials in Pharmacovigilance
• Patient Alert Cards in Pharmacovigilance
• Risk Communication in Pharmacovigilance
• Measuring the Effectiveness of Risk Minimisation Measures

Reproductive Safety

• Teratogenicity in Pharmacovigilance
• Pregnancy Exposure Monitoring
• Pregnancy Registries
• Medicines and Pregnancy: Pharmacovigilance Considerations
• Reproductive Toxicity in Drug Development

Pharmacoepidemiology

• Drug Utilisation Studies
• Post-Authorisation Safety Studies (PASS)
• Post-Authorisation Efficacy Studies (PAES)
• Real-World Evidence in Pharmacovigilance
• Observational Studies in Pharmacovigilance

Benefit-Risk Assessment

• Benefit-Risk Assessment in Pharmacovigilance
• Signal Detection
• Signal Validation
• Signal Assessment
• Emerging Safety Issues

Pharmacovigilance Systems

• The Qualified Person Responsible for Pharmacovigilance (QPPV)
• The Pharmacovigilance System Master File (PSMF)
• Pharmacovigilance Inspections
• Pharmacovigilance Audits
• Corrective and Preventive Actions (CAPA)
• Quality Management Systems in Pharmacovigilance

Regulatory Framework

• Good Pharmacovigilance Practices (GVP)
• European Medicines Agency (EMA)
• Commission Implementing Regulation (EU) No 520/2012
• Directive 2001/83/EC
• Regulation (EC) No 726/2004

The concepts described in these articles complement Pregnancy Prevention Programmes and provide a broader understanding of how reproductive safety is managed throughout the medicinal product lifecycle.

References

European Union Legislation

1. European Parliament and Council. Directive 2001/83/EC of 6 November 2001 on the Community code relating to medicinal products for human use, as amended.

2. European Parliament and Council. Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing the European Medicines Agency, as amended.

3. European Commission. Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 and Directive 2001/83/EC.

European Medicines Agency

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems (Rev. 2).

2. European Medicines Agency. Good Pharmacovigilance Practices (GVP) Module XVI – Risk Minimisation Measures: Selection of Tools and Effectiveness Indicators (Rev. 3).

3. European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP).

4. European Medicines Agency. Risk Management Plan guidance and associated templates.

5. European Medicines Agency. Product-specific Pregnancy Prevention Programme guidance where applicable.

International Guidelines

1. International Council for Harmonisation (ICH). ICH E2E: Pharmacovigilance Planning.

2. Council for International Organizations of Medical Sciences (CIOMS). Practical Approaches to Risk Minimisation for Medicinal Products.

3. Council for International Organizations of Medical Sciences (CIOMS). Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals.

Scientific Literature

1. Relevant peer-reviewed literature relating to:

2. reproductive toxicology;

3. teratogenicity;
4. pharmacoepidemiology;
5. pregnancy registries;
6. pregnancy exposure monitoring;
7. additional risk minimisation measures;
8. effectiveness evaluation of Pregnancy Prevention Programmes.

Where product-specific examples are discussed, readers should consult the latest approved Summary of Product Characteristics, Package Leaflet and Pregnancy Prevention Programme materials for the individual medicinal product.